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Abstract
AN EVALUATION OF DIFFERENCES IN MOTIVATIONS TO RECEIVE CERVICAL
CANCER SCREENING AND FOLLOW-UP CARE BETWEEN BLACK AND WHITE
WOMEN

By: Ashlee Nicole Sawyer, M.S.
A dissertation submitted in partial fulfillment of the requirement of the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2019
Director: Eric G. Benotsch, Ph.D
Associate Professor of Psychology
Department of Psychology

Background: Cervical cancer among Black women is a major individual and public health
concern. Despite advancements in medical technology and policy, disparities in cervical cancer
diagnosis and mortality still exist between White and Black women, with Black women having
higher rates of diagnosis (10.0 vs 7.1 per 100,000) and mortality (4.1 vs 2.0 per 100,000).
Previous studies have focused heavily on barriers to obtaining cervical cancer screening among
Black women and efforts to improve screening rates. Despite speculation by researchers that gaps
in receipt of quality follow-up care may contribute to disparities, its role in disparate mortality
rates between Black and White women has yet to be formally studied.
Purpose: The goals of the present research were to (1) assess differences in Pap screening rates
and (2) rates of adherence to recommended follow-up care after abnormal Pap results between
Black and White women, (3) evaluate how specific factors of the Health Belief Model (HBM)
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influence the decision-making process for obtaining Pap screening and (4) receiving
recommended follow-up Pap care, and (5) evaluate the role of ethnic centrality as a factor in
health decision-making.
Results: Results indicated that HBM facets functioned similarly in predicting engagement in Pap
screening and follow-up care, although there were differences in the influence of different facets
by race. Ethnic centrality showed little applicable influence on adherence to follow-up care
among Black women. An exploratory analysis revealed that doctor recommendation was the
most influential factor predicting follow-up care use for both racial groups.
Conclusion: The present study offers support for increased education and training on provider
recommendation of appropriate follow-up care, as well as effective provider communication of
results and services using messaging that appeals to the values and concerns of patients.

1
An evaluation of differences in motivations to receive cervical cancer screening and follow-up
care between Black and White women

Introduction and Background
Cervical Cancer
What is Cervical Cancer? Cervical cancer occurs when malignant cells develop in the
cervix, which is a structure of tissue that attaches the lower section of the uterus to the upper
section of the vaginal canal (Center for Disease Control and Prevention [CDC], 2014). The
cervix serves many functions, including acting as a physical barrier preventing sexually
transmitted infections (STIs) from entering the uterus, altering the consistency of mucus
production to permit or prohibit conception, and dilating to allow childbirth to occur or tissue to
be expelled during menstruation.
What is Human Papillomavirus? Cervical cancer most commonly results from infection
by certain high-risk strains of Human Papillomavirus (HPV) that are sexually transmitted
(Ramondetta, 2013; U.S. Preventive Services Task Force [USPSTF], 2018). HPV is the most
commonly occurring STI in the United States, and accounts for an estimated 14.1 million of the
20 million new STI diagnoses that occur each year (CDC, 2013). It is estimated that 80% of
Americans will have contracted HPV in their lifetime (American Sexual Health Association,
2019), and 79 million Americans are currently infected with at least one strain of HPV (CDC,
2016). Although HPV will largely be discussed throughout this project in terms of the potential
for certain specific strains to negatively influence the cervix of cisgender women, people can
become infected with HPV regardless of gender and HPV can influence many different body
parts and systems.
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While over 200 types of HPV exist, there are about 40 different strains that can infect the
genitals (including the cervix, vagina, vulva, rectum, anus, penis, and scrotum), mouth, and
throat (Planned Parenthood Federation of America [PPFA], 2018). Some of these HPV strains
may cause warts to develop, while others may lead to problematic cell changes that can result in
cancer over time. Of the types of cancer that can result from HPV infection, cervical cancer is
the most commonly occurring (CDC, 2012). Other strains outside of these 40 types may cause
warts to develop elsewhere on the body, such as on the hands and feet; however, these strains are
not sexually transmitted and will not be the focus of this work. HPV 16 and 18 are the viral
strains that are most often responsible for cervical cancer diagnoses, with HPV 16 accounting for
50% and HPV 18 accounting for 20% of these diagnoses (Ramondetta, 2013). Still, there are
other strains of HPV that have been linked to cervical cancer, and up to 40% of individuals who
receive a cervical cancer diagnosis are infected with more than one strain of HPV (Ramondetta,
2013). Most HPV infections are able to be cleared naturally by the body’s immune system over
time; however, the high prevalence of HPV and likelihood of exposure to high-risk HPV strains
indicate that those who have a cervix remain at risk for cervical cancer. Further, having a poorer
immune system or becoming infected with more persistent strains of HPV can result in the body
being unable to clear the virus(es) on its own, thus placing individuals at increased risk for
developing cervical cancer.
How prevalent is cervical cancer? At one time, cervical cancer was the leading cause of
cancer death among women in the U.S. (NIH, 1996). Though rates of diagnosis and mortality
have fallen by around 75% over the past 50 years, cervical cancer is still the third most common
gynecological malignancy among women in the United States (U.S. Cancer Statistics Working
Group, 2015). Despite our advances, each year, around 12,000 individuals are diagnosed and
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about 4,000 die from cervical cancer (CDC, 2014). In 2018, the estimated number of women in
the U.S. who were living with cervical cancer was 289,696 (SEER, 2019). For 2019, the
estimated number of new cases is 13,170 and the estimated number of deaths is 4,250 (National
Cancer Institute [NCI], 2019). The median age at diagnosis is 50 years old; however, graphing
cervical cancer diagnosis by age shows that women are most often diagnosed between the ages
of 35-45 years old (NCI, 2019).
How can cervical cancer be prevented?
Abstinence. As HPV strains that affect reproductive organs are contracted through sexual
contact, the easiest way to avoid HPV infection that may lead to cervical cancer is to practice
abstinence. For those who are sexually active, it is suggested that barrier methods (e.g., latex
condoms, dental dams) are used for protection against direct skin-to-skin contact that may result
in transmission of the HPV virus (CDC, 2016).
Vaccination. It is also widely suggested that individuals receive the HPV vaccination,
which protects against the strains of HPV that most commonly result in cervical cancer (CDC,
2012; Department of Health and Human Services [DHHS], 2013). The Gardasil 9 HPV
vaccination specifically targets and protects against the two highest risk HPV strains involved in
cervical cancer (HPV-16 and HPV-18), as well as five other strains that are linked with cancer
(HPV-31, 33, 45, 52, and 58) and strains that cause the majority of cases of genital warts (HPV-6
and HPV-11) (Bailey et al., 2018; Kahn, Lan, & Kahn, 2007; Merck Vaccines, 2019). The HPV
vaccine is given in a series of two to three doses administered across a six- to 12-month span
depending on age range (Bailey et al., 2018; Merck Vaccines, 2019; National Cancer Institute
[NCI], 2014).
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When first approved in 2006, vaccination was recommended for adolescent girls from
11-12 years old (but could be administered beginning at the age of 9), and a similar
recommendation was made for adolescent boys beginning in 2011 (NCI, 2014). Since then,
recommendations have expanded even further. As of August 2019, the CDC recommends that
vaccination occur before an individual reaches 15 years of age (Meites et al., 2019). This practice
is recommended for two reasons: (1) HPV vaccines result in a higher immune response in those
who are of preteen or young teen age, and (2) the vaccine is more effective at preventing
infection if the series is completed before an individual becomes sexually active (Bailey et al.,
2018). Still, recent numbers indicate that among those 11-13 years old, only 36% of girls and
14% of boys have been vaccinated (Bailey et al., 2018).
It is also recommended that catch-up doses be administered to men through age 21, as
well as women and “certain special populations” (i.e., gay or bisexual men and those who have
lowered immune systems) through age 26 (Bailey et al., 2018; Meites et al., 2019). The most
recent update to these recommendations includes those in the 27-45 age range. Clinical trials
have shown efficacy in preventing HPV infections, and the CDC now recommends that shared
clinical decision-making between provider and patient be utilized to determine whether those
falling within this age range would benefit from vaccination (Meites et al., 2019). For example,
those who are not in a mutually monogamous sexual partnership and/ or have new sexual
partners are at risk for acquiring a new HPV infection and may benefit from vaccination (Meites
et al., 2019). Those who receive the vaccine after age 15 will receive a schedule of three doses,
with the second dose occurring 1-2 months after the first, and the third occurring 6 months
following the second dose (Meites et al., 2019).
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Cervical Cancer and HPV Screening. Medical advances have significantly reduced both
cervical cancer diagnosis and mortality rates among those with a cervix, by allowing cancer to be
detected at its earliest stages though Papanicolaou (Pap) smear testing (Parrish, 2016;
Surveillance, Epidemiology, and End Results [SEER], 2019). During a Pap smear, a sample of
cells is collected from the cervix by a medical professional and sent off to a medical lab to be
evaluated for cell changes that indicate cancerous or pre-cancerous conditions. While Pap smears
test for abnormal cell developments that result from HPV infection, they do not test for the HPV
viruses themselves. HPV testing, on the other hand, does detect the presence of the HPV virus,
which can develop into abnormal cell changes (i.e., cervical dysplasia) in the future that may
ultimately result in the formation of cancerous cells.
It is currently recommended that 21-29 year olds with a cervix obtain Pap testing at 3year intervals as long as results remain normal (USPSTF, 2018). It is suggested that those aged
30-64 years old obtain either a Pap test at 3-year intervals, receive high-risk HPV testing every 3
or 5 years, or receive both Pap testing and high-risk HPV testing every 5 years (American
College of Obstetrics & Gynecology [ACOG], 2016; USPSTF, 2018). Current recommendations
also state that if those aged 65 and older have had a history of normal results for the previous 10
years, they may be able to stop testing (USPSTF, 2018). However, this particular guideline has
recently been called into question after research has surfaced showing significant rates of
cervical cancer diagnosis after age 65 (Dilley, O’Donnell, Smith, Bae, & Huh, 2018). In this
work, data from the SEER and National Cancer databases were used and showed that between
18.9-19.7% of cervical cancer diagnoses from 2000-2014 had been among women above the age
of 65 (Dilley et al., 2018). For these and other reasons, screening practices and intervals should
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be based on individuals’ circumstances and health history, and should be part of an ongoing plan
of care between an individual and their medical provider.
Screening recommendations are different from those previously listed for those who are
at a higher risk of developing cervical cancer, such as those with a history of cervical cancer;
those who are HIV positive or immunosuppressed; and those with a history of exposure to DES
(diethylstilbestrol) while in utero (Vegunta Files, & Wasson, 2017). [DES is a synthetic form of
estrogen that was prescribed to some pregnant women between 1938-1971 with the intention of
preventing miscarriages or premature deliveries; however, it was later found that DES use early
on in pregnancy could cause reproductive issues in the fetus (American Cancer Society, 2015).]
People who are at higher risk for cervical cancer, such as those who fall into the above groups,
may require more frequent Pap testing. Current recommendations instruct these individuals to
consult with their provider about their specific medical history in order to discern the appropriate
timetable for Pap testing given previous Pap results and other risk factors (ACOG, 2016).
The significant reductions in cervical cancer diagnosis and mortality rates over the last
five decades have been largely attributed to the development of effective Pap testing, HPV
testing, and the modification of screening guidelines (Ramondetta, 2013). This is because even
after an HPV virus has been contracted, it can take years or even decades for the viral infection
to transition to the point of cervical dysplasia or develop into cervical cancer. There are typically
no signs or symptoms of infection until years after contraction of the virus (CDC, 2016);
therefore, routine Pap testing is particularly effective at catching cell changes early on and
reducing the window of opportunity for the cell changes to persist unknowingly into cancer
development.
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Types of Abnormal Pap Results.
There are a variety of abnormal Pap results that one can receive, which reflect a range in
severity of abnormal cells or cervical dysplasia.
ASC-US. The result that reflects the lowest level of severity is ASC-US (Atypical
Squamous Cells of Undetermined Significance). This result indicates that abnormal cells have
been detected on the surface of the cervix, but these cells may or may not be dangerous. ASC-US
results are generally considered to be very mild, as they can also indicate other noncancerous
causes, such as infections or inflammation (NCI, 2019).
LSIL. LSIL (Low-grade Squamous Intraepithelial Lesion) refers to finding mild dysplasia
(i.e., slightly abnormal cells) on the surface of the cervix. Because LSIL is caused by strains of
HPV, it is considered to be more serious than ASC-US; however, it is common for the body to
clear LSIL on its own without treatment (NCI, 2019). Still, it is possible for LSIL to become
cancerous and spread. CIN I stands for Cervical Squamous Intraepithelial Neoplasia 1, and is
defined in the same way as a LSIL result; however, CIN results are found when a cervical biopsy
is taken (NCI, 2019). Because these results mean the same thing, LSIL and CIN I results are
grouped together when appropriate.
ASC-H. ASC-H (Atypical Squamous Cells – Cannot exclude High-Grade Lesion) results
indicate the presence of abnormal squamous cells present in the tissue on the outer part of the
cervix. These results may be a sign of more serious results (namely, HSIL), which may develop
into cervical cancer over time if not treated. More testing may be needed to clarify diagnosis of
cells when this result is received (NCI, 2019)
HSIL. A type of moderate or severe dysplasia that is found on the surface of the cervix is
referred to as a High-Grade Squamous Intraepithelial Lesion (HSIL). Abnormal cells in this
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category can range from looking somewhat to very abnormal, and if no treatment is received
then these cells may become cancer and spread to nearby healthy tissue (NCI, 2019).
CIN II. Cervical Squamous Intraepithelial Neoplasia II (CIN II) results indicate that a
cervical biopsy has been done and abnormal cells have been found on the surface tissue of the
cervix. While this is not a cancer diagnosis, the result does refer to high-grade or moderate
dysplasia and it may develop into cancer if treatment is not received. Appropriate treatment for
this diagnosis may include cryotherapy, laser therapy, Loop Electrosurgical Excision Procedure
(LEEP), or cone biopsy to remove or destroy abnormal tissue (NCI, 2019). Each of these
treatment options are described in further detail in the next section.
CIN III. Severely abnormal cells that are found on the surface of the cervix through the
completion of a cervical biopsy are referred to as Cervical Squamous Intraepithelial Neoplasia
III (CIN III). This result indicates high-grade or severe dysplasia, and is also sometimes referred
to as Stage 0 Cervical Carcinoma in Situ (NCI, 2019). The treatment options for this diagnosis
are the same as those for CIN II.
AGC. A result of Atypical Glandular Cells (AGC) refers to abnormal cells found on the
inner part of the cervix or the lining of the uterus. This result may be a sign of cancer, or could
indicate the presence of other serious medical conditions (NCI, 2019). More testing may be
needed to determine the source and significance of this result.
AIS. Adenocarcinoma In Situ (AIS) results refer to atypical glandular cells, as well. This
result indicates a pre-cancerous condition where these abnormal cells are currently localized to
surface-level cervical tissue but could lead to an invasive adenocarcinoma if left untreated (NCI,
2019).
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Options after Abnormal Pap Results.
If results from a Pap screening test come back as abnormal, but do not show that the
patient currently has cervical cancer, there are methods of treatment designed to prevent the
progression of the abnormal or precancerous cells into cancerous cells. These methods may be
used individually or in combination in order to aid the healthcare provider in diagnosing cell
changes with more specificity and potentially removing the abnormal cells.
Diagnosis of Cervical Dysplasia. There are various methods that providers use to
diagnose (or rule out) specific types or categorizations of cervical dysplasia. One method is a
colposcopy. When colposcopies are performed, a specific microscope (i.e., colposcope) is used
to examine the cervix with increased magnification so that the provider may evaluate the
existence and type of cervical dysplasia based on the appearance of cells (The American College
of Obstetricians and Gynecologists [ACOG], 2015). A provider may decide that in addition to
the colposcopy, it would be advantageous to perform a cervical biopsy. During a cervical biopsy,
a large cluster of cells that appear to be abnormal are collected from the surface of the cervix and
sent to a lab to be assessed. A provider may also decide that endocervical curettage should be
performed, which involves collecting clusters of abnormal cells from the inside of the cervical
canal for further analysis (ACOG, 2015).
Treatment of Cervical Dysplasia. There are two types of methods used for treatment once
a diagnosis of the presence of precancerous cells is made: excisional treatments and ablation
treatments. Excisional treatments consist of either a LEEP (Loop Electrosurgical Excision
Procedure), which is the most common treatment used and involves using electrical current
running through a wire loop to remove the part of the cervix with abnormal cell growth; or
conization, where a cone-shaped portion of the cervix containing abnormal cells is removed
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(ACOG, 2016). Ablation treatments, on the other hand, consist of either cryotherapy, where the
abnormal cells are frozen and naturally detach; or laser therapy, where the tissue is destroyed
using a focused beam of light (ACOG, 2016).
Often, once treatment is administered, more frequent Pap and/ or HPV testing is
recommended in order to follow up more closely on any subsequent cervical changes.
Conversely, some types or stages of cervical dysplasia do not require treatment, as they may
consist of more minor cell changes that the body may be able to clear up on its own (e.g., results
indicating ASC-US, LSIL, or CIN I). Still, more frequent Pap and/ or HPV testing is typically
recommended when this is the case, to monitor any new developments and catch any additional
changes early on.
Health Disparities in Cervical Cancer Diagnosis and Mortality
Despite the overall reduction of cervical cancer diagnoses and mortality that has been
seen in recent decades, disparities still exist between White and Black women. The American
Cancer Society (2016) reports that Black women experience higher rates of cervical cancer
diagnosis than White women (10.0 vs 7.1 per 100,000 women), as well as double the rate of
mortality (4.1 vs 2.0 per 100,000 women, respectively; American Cancer Society, 2016).
However, more recent work that accounts for personal history of hysterectomy indicates the
existence of even more severe disparities, and reports mortality rates of 10.1 vs 3.2 per 100,000
women among Black and White women, respectively (Beavis, Gravitt, & Rositch, 2017).
Although adjusted diagnosis rates are not reported, this work suggests that disparities in
mortality rates had previously been underestimated by 44%. To put these new statistics into
perspective, the authors compared the adjusted cervical cancer mortality rates to global rates, and
found that the mortality rate among White women mirrored that found in other developed nations
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(e.g., Europe, Australia/ New Zealand, Japan) at 3.3 per 100,000 women, while rates for Black
women were in-line with those of less developed nations (e.g., all of Africa and Asia, not
including Japan) at 9.8 per 100,000 (Beavis et al., 2017). Although Black women are more likely
than any other racial/ethnic group to die from cervical cancer in the U.S., prior work has shown
that Black women remain largely unaware of their increased rates of risk (Parrish, 2016).
Pap Screening. Disparities in diagnosis and mortality persist even as disparities in Pap
screening behavior have narrowed, with Black women now obtaining Pap screening at rates that
are equal to those of White women (American Cancer Society [ACS], 2016). Still, much of the
research focused on reducing racial disparities in cervical cancer diagnosis and mortality
continue to be aimed at increasing Pap screening behaviors of Black women (Ackerson, 2010;
Bazargan, Bazargan, Farooq, & Baker, 2004; Bellinger, Millegan, & Abdalla, 2015; Strohl et al.,
2015; Weragoda et al., 2016). Both qualitative and quantitative studies have discussed various
factors that result in non-adherent Pap screening behaviors among Black women, including
socioeconomic status (SES; Bellinger et al., 2015; Weragoda et al., 2016), lack of adequate
insurance coverage (Bellinger et al., 2015), knowledge about cervical cancer (Strohl et al., 2015),
poor patient-provider communication and relationships (Ackerson, 2010; Bazargan et al., 2004),
and ethnic identity (Bellinger et al., 2015).
Low SES and lack of insurance coverage result in decreased access to screening, with
some women relying on free or reduced-cost screening programs or opting to delay their care
(Bellinger et al., 2015). Other studies have even noted that rates of cervical cancer incidence and
mortality within some low-income communities in the U.S. come close to mirroring those rates
documented in developing nations (Kahn et al., 2012; Jemal et al., 2013). Lack of knowledge
about the causes of cervical cancer, how it can be prevented, and the use of Pap tests to screen
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for it have each been related to lower rates of screening among Black women (Bellinger et al.,
2015; Strohl et al., 2015).
As previously stated, studies have also found that many Black women are unaware of
their increased risks related to cervical cancer and the need to obtain screening (Bazargan et al.,
2004). Patient-provider relationships have been thoroughly studied, and results have shown that
receiving suggestions to receive screening and receiving health education from providers is a
significant predictor of screening behavior (Johnson, Mueller, Eliason, Stuart, & Nemeth, 2016;
Tracy, Schluterman, & Greenberg, 2013). Along with this, effective communication, trust, and
the presence of shared decision-making between the patient and their provider have all been
related to higher rates of screening (Ackerson, 2010; Bazargan et al., 2004; Bellinger et al.,
2015).
Various provider interventions and culturally-focused health campaigns developed
specifically to target Black women have been employed to encourage increased screening;
however, mortality rates have not been significantly reduced (Parrish, 2016). These efforts may
have positively influenced Pap screening rates over time, though, as it is currently reported that
Black women now have equal rates of Pap screening to White women (ACS, 2016). However, it
stands to reason that barriers other than those related to access to and utilization of Pap screening
must remain, as Black women have been found at the time of cancer diagnosis to be older and to
have a more advanced stage of cancer than White women even despite having roughly equal
rates of Pap screening (Weragoda et al., 2016). The aforementioned differences in age and
cancer stage at time of diagnosis have been found to be strong predictors of cervical cancer
mortality in Black women (Brooks, Baguet, Gardner, Moses, & Ghosh 2000; Eggleston et al.,
2006); and though it has not been formally studied, it has been suggested that these differences
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likely result from receiving no follow-up care or follow-up care of poor quality after receiving
abnormal Pap test results (Benard et al., 2012; Brandt et al., 2006; DeSantis, Naishadham, &
Jemal, 2013; Horner et al., 2011; Weragoda et al., 2016).
Follow-Up Care as a Barrier. Some qualitative research has shown that lack of knowledge
about follow-up care, the costs associated with such care, and the patient-provider relationship are all
influential factors for ethnic minority women when making decisions about obtaining recommended
follow-up care (Bellinger et al., 2015; Brandt et al., 2006; Coker, DeSimone, Eggleston, White, &
Williams, 2009). Bellinger and colleagues (2015) noted that Black women reported little recollection
about the follow-up care recommended by their provider, as well as limited access to follow-up care
services that were recommended after they received their abnormal Pap results. Other research has
suggested that the quality and appropriateness of treatment following abnormal Pap results may
contribute to the racial disparities seen in survival rates, as ethnic minority women often do not share
the same level of access to high quality health care that White women do (Hicks, Yap, Matthews, &
Parham, 2006; Weragoda et al., 2016). Despite these speculations, the role of receipt of follow-up
care in the disparate cervical cancer mortality rates between Black and White women has yet to be
formally studied.
Disparities based on socioeconomic status. Socioeconomic status (SES) has been
implicated as a root cause of health disparities in cervical cancer diagnosis and mortality rates
(Weragoda et al., 2016). SES can and has been operationalized and discussed in various forms
within the literature. However, in relation to healthcare systems and service use, it is most often
discussed within the frame of affordability and access, not just to health care, but to high quality
health care. Consideration is often given to the ability to pay for services out of pocket, the
availability of social aid programs focused on provision of health care services, and access to
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health insurance coverage. A particularly important aspect of access to health insurance coverage
is access to high-quality health insurance coverage (i.e., the ability of individuals to not be underinsured), as access to low-quality insurance results in people having insurance coverage by title,
but still not possessing the ability to afford the health care services that they need.
Prior work has shown that people are more likely to forego health care services–including
preventive services–if they lack any form of health insurance coverage, which is a behavior that
has been documented as subsequently resulting in poorer health outcomes (Kaiser Commission
on Medicaid and the Uninsured, 2006). Literature shows that those who are of lower income and
who lack health insurance coverage possess decreased access to Pap screening, with some
women being forced to rely on free or reduced-cost screening programs to obtain necessary care
or delaying their care altogether (Bellinger et al., 2015; Weragoda et al., 2016). A study
conducted by Garfield, Licata, & Young (2014) that collected a nationally representative sample,
showed that only 33 percent of individuals who were uninsured reported receiving preventive
screenings, compared to 67 percent of individuals who had Medicaid coverage, and 74 percent of
those who had private health insurance. Thus, health insurance coverage – and quality health
insurance coverage, specifically – can serve as a significant factor when considering access to
care. Unfortunately, access to any health coverage, especially access to quality health coverage,
in the United States is largely dependent upon level of employment and rate of income. This
means that, in some sense, quality of insurance coverage and SES are inextricably linked in this
country.
The role of the PP(ACA) in working to reduce health disparities.
The Patient Protection and Affordable Care Act (PPACA) may represent a step in a new
direction, as a chief aim of the legislation has been to equalize the quality of insurance coverage and
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access to services irrespective of SES or class standing. The passage of the ACA has resulted in
increased access to preventive cancer screenings, such as cervical cancer screening, for many
individuals (ASPE, 2015). One major accomplishment of the ACA has been the expansion of access
to health insurance coverage – through efforts like Medicaid expansion and the provision of federal
subsidies – to millions of U.S. citizens who did not previously have coverage. While this change has
resulted in increased access to care for a substantial number of people, the establishment of Essential
Health Benefits (i.e., healthcare services that insurance providers are now required by law to cover
with no additional cost-sharing responsibilities for patients) have expanded access to care even
further (ASPE, 2015). Included in these Essential Health Benefits are preventive cancer screenings,
such as cervical cancer screening. This means that individuals are now supposed to have access to
these preventive screening services at no out-of-pocket cost to them (Kaiser Family Foundation,
2013), which has the potential to significantly reduce barriers to certain preventive care. Altogether,
this legislation reflects the desire for a cultural shift away from treatment and toward prevention of
health issues.
However, the ACA is not without its faults. The final draft of the ACA legislation did not
include the initially proposed requirement that states expand their Medicaid coverage to those living
at or below 138 percent of the federal poverty level. Instead of including a blanket requirement for all
states to expand, the decision to expand, Medicaid coverage using these or other guidelines was left
up to individual states, and financial incentives were offered for states that decided to expand.
Although 37states (including Washington D.C.) out of 50 have accepted Medicaid expansion (as of
November 2019), 14 have yet to do so, leaving many of the poorest citizens residing within these
states in a health coverage gap (Kaiser Family Foundation, 2019). Citizens residing in the coverage
gap are deemed ineligible for Medicaid coverage, but are also unable to qualify for federal subsidies
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to offset health insurance costs within the marketplace, since individuals must be situated between
138 and 400 percent of the federal poverty level to qualify for this assistance.
Another significant limitation is that the ACA does not specify diagnostic testing or
treatments as Essential Health Benefits. Specifically considering cases of cervical cancer prevention,
this means that while preventive cancer screenings may be free, any tests that are required to confirm
or formally diagnose precancerous or cancerous cell changes, as well as any treatments for such
abnormal cell changes or cervical cancer at any stage, are still subject to patient cost-sharing. Thus,
patients may be required to pay co-pays, co-insurance rates, or deductibles in order to access these
vital services which are aimed at reducing the chance that their condition would continue into
advanced stages. Because such diagnostic tests and treatments can range in cost and may require the
care of a specialist, lack of high quality health insurance coverage for these services has the power to
severely limit access to life-saving follow-up care and treatment, and ultimately contribute to the
health disparities previously noted.
The Role of Ethnic Centrality in Cervical Cancer Disparities
Qualitative work completed by Bellinger and colleagues (2015) evaluated the factors that go
into deciding whether to obtain a Pap smear among Black women in the American south. A major
theme that emerged in the group discussion was that of ethnic identity. Interestingly, the specific role
of ethnic identity was variable between women and served as both a protective and predictive factor
for cervical cancer care. Some of the women who were interviewed viewed Pap testing as a rite of
passage into womanhood, and many felt that it was their cultural responsibility as Black women to
promote their own health and that of their families and social networks (Bellinger et al., 2015). These
women specifically discussed the need to maintain their own health so that they may be present and
able to care for others, and some extended this idea to the responsibility of educating others about the
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importance of screening (Bellinger et al., 2015). However, for others, cultural identity was
prohibitive of receiving screening. Some women described the script of the “Strong Black Woman,”
in that they were expected to sacrifice their own health and well-being for that of others around them,
which resulted in personal delay or avoidance of care (Bellinger et al., 2015). Still others discussed
the importance of womanhood and motherhood, and reported that fears about the potential for
abnormal results to indicate the need for a hysterectomy or other fertility-compromising treatment
prevented them from seeking care in the first place (Bellinger et al., 2015). The role of ethnic identity
in cervical cancer prevention and care this appears to be an important one that warrants further
explanation.
Theoretical Framework: The Health Belief Model (HBM)
The Health Belief Model (HBM) (depicted in Figure 1) is used to explain how
individuals make choices regarding their health (Janz & Becker, 1984), and has been used to
evaluate decision-making related to preventive service use such as cancer screening behavior
(University of Twente, 2016). Additionally, this model has been used in previous work to predict
cancer screening behaviors specifically among Black women (Hoyo et al., 2005; Johnson, Mues,
Mayne, & Kiblawi, 2008). This model is comprised of five dimensions: (1) susceptibility, (2)
severity, (3) benefits, (4) barriers, and (5) cues to action, which are outlined below and in figure
1 (National Cancer Institute [NCI], 2005).
1. Susceptibility refers to perceptions of risk related to contracting a certain condition,
2. Severity refers to beliefs about how serious an issue or condition is, or how strongly it
may affect one’s health or wellness,
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3. Benefits refer to perceptions about how positive engaging in a certain health action may
be, or how effective the health action may be in reducing susceptibility or severity of a
condition,
4. Barriers refer to beliefs about the negative aspects, outcomes, or costs (e.g., physical,
psychological, etc.) of engaging in the health action, and
5. Cues to action refer to any factors that may trigger engagement in a health action or a
desire to engage in the health action
INDIVIDUAL PERCEPTIONS

Perceptions of
Susceptibility & Severity

MODIFYING FACTORS

LIKELIHOOD OF ACTION

Age, Gender, Ethnicity
Socioeconomic Status
Education level

Perceived Benefits
vs.
Perceived Barriers

Perceived Threat of
Condition or Issue

Likelihood of
Engaging in
Behavioral Change

Cues to Action:
• Education
• Symptoms
• Media Information
Figure 1. The Health Belief Model (modified slightly from Glanz, Rimer, & Lewis, 2002, p.52).
The Health Belief Model and Prevention
This model has been applied to various populations and a plethora of health behaviors,
and has been used to address public health concerns (Conner & Norman, 1996; Chamption &
Skinner, 2016), including preventive health behaviors such as cancer screening, vaccination
uptake, and birth control use behaviors, as well as clinical use behaviors, such as physician visits
(Joseph et al., 2014; University of Twente, 2016; Yarbrough & Braden, 2001). The dimensions
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of the health belief model are substantially supported by empirical evidence as significant
predictors of individuals’ engagement in various health behaviors (Janz & Becker, 1984).
However, in practice, the Health Belief Model is often broken down and used to assess one or
more of the above components on their own rather than testing the influence of the full model on
a health behavior outcome of interest (Crepaz & Marks, 2002; Yarbrough & Braden, 2001).
Previous research evaluating ethnic disparities in cervical cancer screening and mortality
have studied the influence of individual components of the HBM, such as: perceived risk of
susceptibility in relation to screening behavior (Parrish, 2016), the role of cervical cancer
knowledge in perceptions of susceptibility and severity (Strohl et al., 2015) and benefits and
barriers to screening (Bellinger, 2014), and cues to action provided by targeted health campaigns
(Wong et al., 2013; Wong, AbuBakar, & Chinna, 2014) or healthcare providers (Bazargan, 2004;
Bellinger et al., 2015) on Pap screening uptake. Though these dimensions have been evaluated
separately in relation to cervical cancer screening behavior, the HBM (in combination with path
modeling techniques) provides a strong framework through which these dimensions can be
evaluated simultaneously to determine how these factors influence one another and the outcomes
of interest. In the present study, each of these HBM framework dimensions were included in
analyses predicting engagement in Pap screening and the innovative study of receipt of followup care after receiving an abnormal Pap result. Ethnic centrality additionally served as a
moderator under the dimension of ‘cue to action’ predicting receipt of recommended cervical
cancer follow-up care (see Figure 5 for the full model used).
Present Research
The goals of the present research were to (1) assess differences in Pap screening rates
between Black and White women, (2) examine rates of adherence to recommended follow-up
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care following abnormal Pap results between Black and White women, (3) evaluate how specific
factors of the HBM influence the decision-making process for obtaining Pap screening, (4)
evaluate how these factors influence the decision-making process for receiving follow-up Pap
care, and (5) evaluate the role of ethnic centrality as a moderator in health decision-making.
Hypothesis 1a-b: In line with prior research (American Cancer Society [ACS], 2016), it
was hypothesized that (a) Black women would have rates of Pap screening and abnormal Pap
results that were similar to those of White women. As an extension of previous findings, it was
additionally hypothesized that (b) Black women would have lower rates of follow-up care
utilization after receiving abnormal Pap test results.
Hypothesis 2a-f: Drawing on findings from previous research evaluating attitudes,
knowledge, and experiences with Pap screening and follow-up care (Bazargan, 2004; Bellinger,
2015; Parrish, 2016), it was hypothesized that the degree to which various dimensions of the
HBM influence decisions to receive or avoid Pap screening would differ between Black and
White women (See Figure 2). Specifically, it was hypothesized that: (a) demographic variables
for Black and White women would be similarly related to Pap screening, such that age would be
negatively related to Pap screening (i.e., younger women would be more likely to obtain
screening), and education and SES would be positively related to Pap screening (i.e., those who
were more educated and of a higher SES would be more likely to engage in Pap screening)
regardless of race; (b) insurance status would be negatively related to perceived barriers and this
relationship would be stronger for Black women; (c) perceived susceptibility and (d) perceived
severity would be positively related to Pap screening and show a stronger influence among Black
women; (e) perceived barriers would be negatively related to receiving Pap testing and this
relationship would be stronger for Black women, and (f) perceived benefits of receiving Pap
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screening would be positively related to Pap screening and this relationship would be stronger
for White women.

Figure 2. A path model using the components of the Health Belief Model of behavior to depict
the hypothesized relationships between various factors and receipt of Pap screening. This model
was run separately for Black and White women.
Hypothesis 3a-g: In building off of hypothesis 2, it was expected that the degree to
which the dimensions of the HBM influence receipt of follow-up care following an abnormal
Pap result would differ among Black and White women. More specifically, it was hypothesized
that: (a) demographic variables for Black and White women would be similarly related to receipt
of follow-up care, such that younger women, those who are less educated, and those who are of
lower SES would be less likely to engage in follow-up care after an abnormal Pap result
regardless of race; (b) insurance status would be negatively related to perceptions of barriers,
positively related to follow-up care use, and this relationship would be stronger for Black
women; for both Black and White women, higher levels of severity of an abnormal Pap result as
conveyed by a medical provider would be related to increased perceptions of (c) susceptibility
and (d) severity of cervical cancer; (e) perceptions of barriers would be negatively related to
receiving follow-up care after an abnormal Pap result and this relationship would be stronger for
Black women; (f) perceptions of benefits of receiving follow-up care would be positively related
to receiving such care and this relationship would be stronger for White women. It was also
hypothesized that while the directions of the effects will mirror those found for Pap screening,
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(g) the influence of perceived barriers and benefits would be more strongly related to decisions
to obtain follow-up care.

Figure 3. A path model using the components of the Health Belief Model of behavior to depict
the hypothesized relationships between various factors and receipt of follow-up care. This model
was run separately for Black and White women.
Hypothesis 4a-c: Based on previous qualitative work (Bellinger et al., 2015), it was
hypothesized that strong ethnic centrality would serve as a significant moderator for Black
women between perceptions of (a) susceptibility and (b) severity of cervical cancer and the
decision to obtain follow-up care, but would not significantly influence decision-making among
White women. Specifically, it was expected that for Black women, those with stronger ethnic
centrality would be less likely to receive recommended follow-up care (See Figure 4).

Figure 4. Moderation model showing that the relationship between perceptions of susceptibility
and severity and receiving subsequently recommended follow-up care is moderated by the
salience of Black women’s ethnic centrality.
Additionally, it was expected that (c) ethnic centrality would serve as a significant
moderator between perceptions of susceptibility and severity of cervical cancer and receipt of
recommended follow-up care for Black women in the larger HBM model, but that ethnic
centrality would not serve as a significant moderator among White women in this decision-
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making process. More specifically, it was expected that all of the hypothesized relationships
from H3 will be present; however, it was further hypothesized that for Black women, identifying
more closely with one’s ethnicity would weaken the relationship between cervical cancer threat
perceptions and the likelihood of obtaining recommended follow-up care after receiving an
abnormal Pap result, thus resulting in a lower likelihood of obtaining such care (See Figure 5).

Figure 5. A modified version of the path model used to test H3, depicting the additional pathway
of ethnic identity as a moderator between perceived threat and receipt of follow-up care. This
model was run separately for Black and White women.
Method
Participant Recruitment
Amazon Mechanical Turk (MTurk) is a crowdsourcing website where individuals who
are referred to as “workers” complete web-based tasks (usually, but not always) in exchange for
monetary compensation. In MTurk, workers complete “Human Intelligence Tasks” (HITs) set up
by “requesters” (who are the employers) that can range from providing feedback on media
advertisements to passage translation to handwriting transcription to product rating, and more
(Azzam & Jacobson, 2013; Berinsky, Huber, & Lenz, 2012). More recently, MTurk has also
gained the interest of researchers as a platform for conducting research with human subjects.
The use of MTurk has several strengths. One of the most important strengths that the
platform has in relation to this study is the ability to easily reach people who are located all
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across the country. A significant amount of the research evaluating disparities in Black women’s
receipt of cervical cancer screening and treatment care have focused on the experiences of Black
women living in the American south (Bellinger et al., 2015; Carter, 2008; Freeman & Wingrove,
2005; Prabhu Das, 2005; Weragoda et al., 2016; Zhan & Lin, 2014). While these experiences are
certainly important to the conversation, a goal of the present work was to evaluate the
experiences of Black women from diverse geographic locations within the U.S. Another benefit
is the reduced risk of the presence of social desirability bias among respondents (Brinkerhoff,
2016).
Moreover, the platform has successfully been used for cancer disparity research.
Although much cancer disparity research (including work specifically focused on racial
disparities) relies on data from large population surveys such as the National Breast and Cervical
Cancer Early Detection Program (NBCCEDP; Dalzell et al., 2015; Tangka et al., 2015; White &
Wong, 2015), Health Information National Trends Survey (HINTS; Blake et al., 2015; Price,
Koshiol, Kobrin, & Tiro, 2011; Zhao & Nan, 2016), the Behavioral Risk Factor Surveillance
System (BRFSS; Chen, Kessler, Mori, & Chauhan, 2012; Gandhi et al., 2015; Herrera et al.,
2012), and the National Health Interview Survey (NHIS; Forney-Gorman & Kozhimannil, 2016;
Prince et al., 2011; Solomon, Breen, & McNeel, 2008; Sirovich & Welch, 2004), a substantial
portion of more recent work has turned to MTurk data collection to gain more insight into
individual experiences related to cancer prevention behaviors. MTurk has been used to evaluate
knowledge, perception, and intention specifically related to cervical cancer screening and
prevention (Porter, Amin, & Bednarczyk, 2018), online cancer information-seeking (Chae,
2015), and attitudes and well-being of cancer survivors (Arch & Carr, 2015). Additionally, the
crowdsourcing site has been used to evaluate other similar research topics, such as knowledge
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and attitudes related to ovarian cancer (Carter, DiFeo, Bogie, Zhang, & Sun, 2014), lung cancer
(Zide et al., 2015), breast cancer screening (Yeh, Schnur, Margolies, & Montgomery, 2015),
sexual behavioral factors (Beymer, Holloway, & Grov, 2018), and infertility (Farrell, Brennan, &
Lanham, 2018).
In other countries, work related to cervical cancer screening has been completed using
crowdsourcing sites outside of MTurk. For instance, work being conducted among populations in
Britain (Marlow, Ferrer, Chorley, Haddrell, & Waller, 2018) and comparing samples in Australia
and the U.S. (Schmid et al., 2017) used Qualtrics and Survey Monkey, respectively, for data
collection. This may be related to the fact that the majority of MTurk workers are from the U.S.
(75%) or India (16%), with only 0.7 percent of MTurk workers living in Britain, and even fewer
living in Australia (Difallah, Filatova, & Ipeirotis, 2018). Still other studies surveying cancerrelated perceptions and behaviors in countries such as Canada (Duffet-Leger, Letourneau, &
Croll, 2008) and Korea (Kim, 2014) have relied on the collection of data from university
samples.
A strength of MTurk is that it offers the ability to collect data from hundreds of
participants in the span of a few hours (Litman, Robinson, & Abberbock, 2017). While previous
research using MTurk has been able to collect decently sized samples of women (Carter et al.,
2014; Porter et al., 2018; Yeh et al., 2015) and cancer survivors (Arch & Carr, 2015; Chae,
2015), a potential concern for the present project was the ability to collect data from selfidentified Black women. The U.S. Census Bureau population estimates for 2017 show that Black
citizens comprise slightly over 13 percent of the population. However, Black women make up
just over seven percent of the U.S. population (U.S. Census Bureau, 2017). Since the proportion
of Black women in the country is so small relative to the proportion of White women, it was
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anticipated that there would be more difficulty involved in recruiting the amount of Black
women needed to establish power for the study analyses.
While the use of MTurk is unlikely to provide the same level of access as in-person study
recruitment might, it does offer the ability to collect Black women from geographically diverse
locations at a rate that appears to be higher than some other crowdsourcing platforms. Schmid
and colleagues (2017) did not report demographic information related to race; however, Marlow
and colleagues (2018) reported that 8.3 percent of their Qualtrics sample identified as Black and
73 percent identified as White. Interestingly, a study evaluating attitudes towards cervical cancer
screening recommendations in the U.S. that used Qualtrics for data collection reported a far
larger sample of White participants (82%), although they did not break down the participation of
other racial groups beyond categorization as “Non-White” (Gerend, Shepherd, Kaltz, Davis, &
Shepherd, 2017). MTurk workers fluctuate in their participation on the site; however, previous
work has shown that MTurk can be used to collect samples that are more racially diverse than
Qualtrics (Beymer et al., 2018), social media recruitment, and university samples (Casler, Bickel,
& Hackett, 2013). Additionally, some of the previously mentioned studies have been able to
recruit Black women at a rate that is higher than the U.S. Census figures for Black women in the
population (Farrell et al., 2018; Yeh et al., 2015).
Because MTurk was not originally developed to meet the needs of social science
researchers, a newer platform developed with the intention of serving researchers, TurkPrime,
was used (Litman et al., 2017). TurkPrime links to requesters’ MTurk accounts and is designed
to sample the same pool of MTurk workers; however, TurkPrime offers additional controls that
allow researchers to collect data more efficiently, with less biased data, and at a lower cost. One
of the benefits of this platform is the addition of a control to automatically assign qualifications.
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This control allows researchers to reduce the risk of multiple survey completions by the same
person, by assigning a “qualification” to workers after they complete the survey. This
qualification assignment will result in workers who have previously completed the study not
being able to access it again in the future.
TurkPrime also provides a control called “microbatch” which allows researchers to set
small batch collections to open at pre-determined times throughout the day. Bias in participant
characteristics based on the day of the week and time of day that data collection batches are
released has been noted, as certain types of people in certain areas of the country are more likely
to be logged onto MTurk at certain times (Litman et al., 2017). The addition of this feature aids
in the reduction of bias in sampling, since batches can be set up beforehand to be released at
various points throughout various days. Perhaps the most beneficial control that TurkPrime
offered for this study was the ability to “restart” a batch. Work by Chilton and colleagues (2010)
has shown that participation in MTurk tasks drops by 70 percent after the first 24 hours after
posting. The “restart” control allows requesters to refresh their data collection batch so that it
appears at the top of the HIT list again. This control has been found to substantially improve
participant engagement with and completion of tasks (Litman et al., 2017).
Sample & Procedure
A national, geographically-representative convenience sample was collected via MTurk
for the current study. A survey was administered through this survey platform to cisgender
women across the United States who were between the ages of 21 and 65. Data were collected
from January until May of 2019. A total of 4,293 surveys were submitted by workers. After
reviewing each submission, data from 2,330 participants (54.27%; 1,171 White women and
1,159 Black women) were retained. The remainder of the submissions were excluded as a result
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of issues such as quality assurance failures, participant errors in the form of incomplete or
duplicate submissions, or multiple submissions emanating from the same IP address (See table 1
below for full exclusion data).
Table 1.
Reasons for participant elimination from dataset
Participants excluded*
n (%)**
529 (26.95)
440 (22.41)

Reason
HIT submitted with fake code or no code
Failed at least 3 quality assurance items
Participant failed identity requirements (either indicated gender/
329 (16.76)
race/ age value that did not permit inclusion)
Duplicate submission by the same MTurk worker
231 (11.77)
IP showed location outside of the U.S.
230 (11.72)
Multiple attempts were shown attached to the same IP address
209 (10.65)
Errors and/ or incoherent free-responses appeared in survey
147 (7.49)
*Reasons listed for participant elimination from dataset are not mutually exclusive
**Percentages taken as a portion of the overall 1,963 participants removed from the dataset
An advertisement was posted on the MTurk website in the form of a HIT (Human

Intelligence Task), which is a single task that MTurk workers have the option to complete. The
description of the study in the advertisement indicated that survey items pertained to perceptions,
experiences, and use of preventive reproductive health services. If workers were interested in
completing the study then they could open the HIT, and they would be directed to the consent
form for the study (see Appendix A for the full consent form). This consent form detailed the
purpose of the study, included an overview of the topics included, and explained that the data
collected from them would remain anonymous and confidential. Participants were also informed
that the study would take roughly 30 minutes to complete, and that they would be compensated
$0.75 upon successful completion, which is slightly above the average rate of compensation for
this platform (Arch & Carr, 2017).
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If individuals chose to participate, then they were directed via a link to the online survey
in Qualtrics. Before accessing the full survey, participants completed a short pre-screening that
collected part of their demographic information and determined their eligibility for participation
based on the inclusion/exclusion criteria listed below. If participants did not meet the inclusion
criteria for the study, then they were notified that they were not eligible to complete the full
study and were directed out of the survey without compensation.
Inclusion/exclusion criteria: Only self-identified cisgender women were recruited for this
study. Inclusion was also limited to women between the ages of 21 and 65, due to the cervical
cancer screening guidelines provided by the U.S. Preventive Services Task Force that
recommend routine screening for the duration of this age range (USPSTF, 2018). Only
participants who self-identified primarily as Black or White were able to participate in the study.
Because MTurk workers are majority White (77%; Sawyer, 2016), separate HITs were created in
order to recruit an equal number of Black and White women, and to ensure that recruitment of
White women was paced equally alongside the speed of recruitment of Black women. One of the
HITs included a filter within their demographic pre-screening survey that excluded anyone who
did not identify as a Black woman, while the other had a filter to exclude anyone who did not
identify as either a Black or White woman.
Screening and informed consent procedures: Due to the online nature of this study, a
waiver of documentation of informed consent was acquired in favor of electronic consent;
therefore, participants were directed to an informed consent page that provided details of the
study and their participation. Participants were required to indicate that they had read this
consent form and wished to participate in the study in order to progress to the survey prescreener. Participants were informed via the consent document that certain demographic
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characteristics were required to participate in the full study, and that they would be required to
respond to a brief set of demographic questions before proceeding to the actual study survey.
Participants were not informed of the desired demographic characteristics (i.e., age range,
gender, and race requirements) before their completion of the demographic questions.
After providing responses to the demographic survey, respondents who did not meet the
inclusion criteria for participation in the study were informed of this and were not allowed to
proceed, while respondents who did meet the inclusion criteria for the study were allowed to
continue. The latter group was then able to participate in the rest of the study via completion of
online questionnaires, which took approximately 30 minutes. Compensation was provided to
participants upon successful completion of the study via the MTurk payment mechanism
(automatic deposit to their account). Participants were informed via the consent document that in
order to receive compensation for their participation, they must correctly respond to seven out of
ten quality assurance questions (seven quantitative and 3 qualitative open response) that were
placed randomly throughout the study. Successful participants were paid $0.75 upon successful
completion of the study. Participants were also required to enter the same six-digit code into both
the Qualtrics survey and MTurk HIT page in order to receive compensation. Once the codes
were matched across online platforms and quality assurance items were checked for correctness,
compensation was authorized.
Both MTurk and Qualtrics operate through secure servers, and the only identification of
the participant was present in the identification value assigned to the participant by MTurk. IP
addresses were collected initially as a quality control measure to ensure participants had not
submitted duplicate entries, but were removed from the dataset once data quality had been
evaluated, and thus were not stored with the data. Because no identifying information was stored,
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participation in the study remained anonymous. All study procedures were approved by the
Institution Review Board (IRB) at Virginia Commonwealth University prior to data collection.
Power Analysis
Although 2,330 of the 4,293 submissions were initially retained for analyses, an
additional 82 participants (45 White women and 37 Black women) were removed from the
dataset. These 82 participants indicated that they had undergone a hysterectomy wherein their
cervix had been removed, which meant that they would not need to obtain Pap screening and
thus should not be included in analyses. The final sample size included 2,248 individuals (1,125
White women and 1,123 Black women).
Post hoc power analyses were run separately for chi square and moderation analyses
using G*Power software (Faul, Erdfelder, Buchner, & Land, 2009). Power analyses for chi
square analyses by race showed that (1) for the outcome of ever receiving abnormal Pap results
with the participants in the sample who reported ever receiving Pap screening (n=2,008), it was
determined that this sample size was sufficient to detect a small effect (0.1) at 0.94 (94%), (2) for
the outcome of receiving recommended follow-up care including only participants who ever
reported an abnormal Pap result and had a medical provider recommend they receive follow-up
care (n=624), the sample size was sufficient to detect a small effect (0.15) at 0.93 (93%), and (3)
for the outcome of receiving recommended follow-up care for more severe abnormal Pap results
including only participants who ever reported a more severe abnormal Pap result and had a
medical provider recommend they receive follow-up care (n=116), the sample size was sufficient
to detect a moderate effect (0.35) at 0.93 (93%).
In evaluating power for moderation analyses, it was determined that for analyses
including only Black women (n=294), the sample size was sufficient to detect a small effect
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(0.05) at 0.97 (97%). Moderation analyses including only White women (n=366) were
determined to be powered to detect a small effect (0.15) at 0.99 (99%).
Because software is not available to calculate post hoc power for path models, a priori
power analyses were utilized to calculate power for each of the hypothesized path models using
the a priori structural equation modeling power calculator created by Soper (2017). A power
analysis for the theorized H2 model predicting Pap screening behavior that included 5 latent
variables and 32 observed variables, a desired power level of 0.90 (90%), an error probability
level of 0.05, and an anticipated effect size of 0.10 showed that a sample size of 2,008 was
needed in order to detect small effects, and that a minimum of 269 participants were needed in
order to test the model structure. Thus, the sample size of 2,248 participants was determined to
provide adequate power at 0.90 to test for small effects.
A power analysis for the theorized H3 model predicting utilization of follow-up care and
included 6 latent variables and 37 observed variables, a desired power level of 0.90 (90%), an
error probability level of 0.05, and an anticipated effect size of 0.18 showed that a sample size of
629 was needed in order to detect small-medium sized effects, and that a minimum of 227
participants were needed in order to test the model structure. Thus, the sample size of 660
participants was determined to provide adequate power at 0.90 to test for small-medium level
effects.
A power analysis for the theorized H4 model predicting utilization of follow-up care and
included 7 latent variables and 42 observed variables, a desired power level of 0.90 (90%), an
error probability level of 0.05, and an anticipated effect size of 0.18 showed that a sample size of
660 was needed in order to detect small-medium level effects, and that a minimum of 200
participants were needed in order to test the model structure. Thus, the sample size of 660
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participants was determined to provide adequate power at 0.90 to test for small-medium level
effects.
Measures
Demographics. Participants provided information such as age, gender, race, ethnicity,
sexual orientation, relationship status, educational attainment, employment status, household
income level, number of dependents, and their state of residence (See Appendix B for full study
questionnaire). Gender was asked to ensure that participants who identified as anything other
than a cisgender woman were excluded from the study, and age was asked primarily to ensure
that participants were between the ages of 21 and 65.
The household income level, number of dependents, and state of residence were used to
calculate participants’ standing as a percentage of the federal poverty level (FPL). Percentage of
the federal poverty level was calculated using the 2019 poverty guidelines provided by the US
Department of Health and Human Services, where household size for each participant was
multiplied by the poverty guideline for their state of residence (ASPE, 2019). If participants did
not provide their state of residence, the poverty guidelines for the 48 contiguous states and the
District of Columbia were used.
Health Insurance Information. In order to gain an understanding of participants’
insurance status, questions were posed about the consistency of their health insurance coverage
during the previous year and the type of insurance plan that they have. The item assessing
consistency of health insurance coverage during the previous year was a modified version of the
item used by Geisler and colleagues (2006), and includes the following response options: (1) “I
was not insured at all in the past year,” (2) “I was insured for 1-6 months out of the last year, (3)
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“I was insured for 7-11 months out of the last year,” and (4) “I was insured for all 12 months of
the last year.”
Health insurance plan type was assessed at a broad level of public versus private
insurance, consistent with other studies (Culwell & Feinglass, 2007; Smith & Medalia, 2014).
Private insurance plan types include the following: (a) a plan through an employer, (b) federal
government insurance (for federal employees), (c) a plan through the government exchange/
Marketplace, (d) coverage through a parent’s plan, or (e) coverage through a university plan.
Public insurance plan types include: (a) military insurance (Tricare), (b) Medicaid/ state program
insurance, (c) Medicare, and (d) veteran benefits. Participants also had the option to respond
“I’m not sure.”
Perceived Barriers. Perceived barriers were assessed using a measure of barriers
specifically related to cervical cancer screening. The “barriers” subscale of the Health Belief
Model Scale for Cervical Cancer and Pap Smear Test developed by Guvenc and colleagues
(2010) was used. This subscale included 14 items measured using a 6-point Likert scale ranging
from “strongly disagree” to “strongly agree,” and assessed perceptions of various types of
barriers (e.g., tangible financial- and resource- based barriers, emotional barriers) related to
obtaining cervical cancer screening. For the overall sample, the reliability of this this subscale
was α = .85 (see Table 2 for reliability values by race). An example item for this scale is “I have
other problems more important than having a Pap smear test in my life.” A 13-item modified
version of this scale was used to assess perceptions of barriers related to obtaining cervical
cancer follow-up care following an abnormal Pap result, and the same 6-point Likert scale was
used. Reliability for this measure was α = .83 (see Table 2 for reliability values by race). For this
scale, the item “I am too old to have a Pap smear test regularly” that was present in the perceived
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barriers measure for Pap screening was removed, rather than re-worded to reflect follow-up care.
An example item for this scale is “I am afraid to have follow-up diagnostic tests done for fear of
a bad result.”
Perceived Benefits. Perceived benefits were assessed using a measure of benefits
specifically related to cervical cancer screening derived from another subscale of the Health
Belief Model Scale for Cervical Cancer and Pap Smear Test (Guvenc, Akyuz, & Han Acikel,
2010). The “benefits” subscale included 5 items and was measured using a 6-point Likert scale
ranging from “strongly disagree” to “strongly agree.” The reliability of this scale was α = .73
(see Table 2 for reliability values by race). An example item for this scale is “Having regular Pap
smear tests will decrease my chances of dying from cervical cancer.” A 4-item modified version
of this scale was used to assess perceptions of benefits related to obtaining cervical cancer
follow-up care following an abnormal Pap result. Reliability for this measure was α = .79 (see
Table 2 for reliability values by race). An example item from this measure is “I think that having
diagnostic tests done after abnormal Pap results is a good way for cervical cancer to be
diagnosed early.”
Perceived Susceptibility. Another subscale established by Guvenc and colleagues (2010)
that included 3 items assessing perceptions of susceptibility related to developing cervical cancer
was used within models for both Pap screening behavior and receipt of follow-up care following
receipt of an abnormal Pap result. This scale used the same 6-point Likert scale as above. For
this sample, the reliability of this measure was α = .92 (see Table 2 for reliability values by race).
An example item for this scale is “I feel I will get cervical cancer sometime during my life.”
Perceived Severity. To evaluate perceptions of how strongly a cervical cancer diagnosis
might influence their health, the “seriousness” subscale of the Health Belief Model Scale for
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Cervical Cancer and Pap Smear Test developed by Guvenc and colleagues (2010) was used.
Participants responded to 7 items using the same 6-point Likert scale as above. The reliability of
this scale was α = .80 (see Table 2 for reliability values by race). An example item for this scale
is “Problems I would experience with cervical cancer would last a long time.”
Ethnic Centrality. Ethnic centrality was measured using a subscale that was adapted from
the Multidimensional Inventory of Black Identity (Sellers et al., 1997). This 5-item ethnic
centrality subscale is designed to assess the extent to which individuals’ ethnic label is central to
how they define themselves. This subscale has been used across a range of ethnic groups of
adolescent age, and has a good overall internal consistency (Fuligni, Witkow, & Garcia, 2005).
For this sample, the reliability of this scale was α = .89 (see Table 2 for reliability values by
race). Participants responded to items asking about their identification with their ethnic group
and background using a 5-point Likert scale that ranged from “1-Strongly Disagree” to “5Strongly Agree.” An example item from this scale is “Being a part of my ethnic group is an
important reflection of who I am.”
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Table 2.
Means, standard deviations, and Cronbach’s alpha coefficients for model predictors by group

Mean (SD)
α Reliability

Perceived
Susceptibility
to Cervical
Cancer
(3 items)

Perceived
Severity of
Cervical
Cancer
(7 items)

Perceived
Barriers to Pap
Screening
(14 items)

Perceived
Benefits of Pap
Screening
(4 items)

Perceived
Barriers to
Follow-Up
Care
(13 items)

Perceived
Benefits of
Follow-Up
Care
(4 items)

3.42 (3.21)
.916

19.72 (6.99)
.798

16.97 (10.96)
.852

14.18 (3.50)
.728

18.51 (11.29)
.866

14.25 (3.66)
.792

3.99 (3.24)
.919
2.85 (3.08)
.908

20.05 (6.28)
.777
19.39 (7.62)
.815

17.12 (10.96)
.855
16.81 (10.96)
.849

14.19 (3.18)
.760
14.18 (3.796)
.745

18.44 (11.27)
.866
19.63 (11.65)
.872

14.26 (3.35)
.768
14.23 (3.95)
.813

Ethnic
Centrality
(5 items)
10.75 (5.19)
.890

Racial Group
White
Black

8.26 (4.62)
.892
13.25 (4.47)
.821
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Severity of Abnormal Pap Test Results as Relayed by a Medical Provider. To evaluate the
severity of participants’ abnormal Pap results, items were developed from concepts present in the
Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey, as well as some of
the research literature (Bellinger et al., 2013; Nolan et al., 2014). Participants responded to 5
items with response options of “Yes,” “No,” and “I don’t know.” An example item for this scale
was “Did the doctor state that the results were potentially harmful to your health?” Response
options were re-coded so that “Yes” received a score of 1, while “No” and “I don’t know”
received a score of 0. A total score was then developed by adding the scores from each of the 5
items, so participant scores ranged from 0-5.
Cervical Care Health Behaviors and Results. Participants were asked to self-report their
medical history related to cervical cancer services and related diagnoses. Individuals were asked
to provide information about Pap screening behavior including whether they had ever had a Pap
smear during their lifetime, if they had received a Pap smear during the previous 3 years, and
how long ago they had received their last Pap smear.
Participants were also asked to report whether they had received an abnormal result on
their most recent Pap screening. For participants who indicated that they had not received an
abnormal result on their most recent Pap, the question was broadened to ask whether they had
ever received an abnormal Pap result. If participants had received an abnormal Pap result in
either of these cases, they were asked to indicate what the official diagnoses for their abnormal
Pap results were. Responses to these items were used to develop a variable describing
experiences of lifetime abnormal Pap results and included data from 660 individuals who had
experienced abnormal results.
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If participants indicated that they had ever received an abnormal Pap result, they were
asked to answer additional questions about whether a medical provider recommended they obtain
additional follow-up diagnostic tests or treatment after receiving the abnormal Pap, which
specific follow-up tests or treatments had been recommended, and whether they obtained the
follow-up care recommended by their medical provider (See Appendix B for full questionnaire).
Additional Medical History. Participants were asked to respond to various items
evaluating their medical history outside of cervical cancer prevention care. Respondents were
asked about previous HIV diagnosis and diagnosis of autoimmune disorders, exposure to DES
while in utero, and previous cervical cancer diagnosis. Medical history including any of these
would be likely to result in a doctor’s recommendation to receive more frequent Pap screening,
and was helpful to factor in when determining the frequency at which participants should be
screened (i.e., if more frequent than every 3 years would be likely).
Additionally, because Pap smear testing requires the presence of a cervix, participants
were asked whether they had a hysterectomy performed and whether their cervix was removed
during this procedure. Thus, participants who reported having a hysterectomy where the cervix
was removed (n=82) were removed from further analyses.
Quality Assurance. In order to reduce random response rates and promote greater data
quality, ten questions were placed throughout the survey as quality assurance items. Seven of
these items were multiple response or true/ false items, and three were open-ended response
items. Participants were notified in the informed consent document that if they failed to correctly
answer seven out of ten of these items then they would not receive compensation. Participant
data was removed for all individuals who failed seven out of ten of the quality assurance items.
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Results
Demographic Information
Sample demographic information is shown in Table 3. The ages of participants ranged
from 21-64 years old, and the average age of participants was 35 years (SD = 10.16). An
independent t test showed that there was a significant difference in age by racial group, though
the means differed by less than two years. The sample also largely consisted of those who had
received their Bachelor’s degree (35.7%) and who were employed full time (55.8%), with no
significant differences based on racial group. There were, however, significant differences in
insurance status during the previous year, with Black women being more likely to have not had
insurance at all or to only have had insurance for 1-6 months out of the year, while White women
were more likely to have had insurance for all 12 months out of the year.
When compared to the 2015 state population estimates published by the U.S. Census
Bureau, the current sample was geographically representative at r = 0.933, p<.001. There were
significant differences in U.S. region of residence by racial group, with Black women being
more likely to live in the South and White women being more likely to live in the Midwest or
West; however, there were no significant racial differences among those living in the Northeast.

Table 3.
Sample demographic characteristics
Black Women White Women
(n=1,123)
(n=1,125)
Characteristic

Means (SD)/
Means (SD)/ t/ Mann-Whitney z /
Percentages (n) Percentages (n)
x2 test values

Age (Years)

34.15 (9.84)

Income

54,428.65
(54,322.521)

35.79 (10.41) t (2246) = 3.832***
65,912.25
(56,977.19)

Z = -7.036***
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Education
Middle school
GED
High School
Vocational School
Associates Degree
Bachelor’s Degree
Graduate Degree (Master’s, Doctorate)

0.0 (0)
2.7 (30)
21.5 (242)
6.4 (72)
19.3 (217)
36.4 (409)
13.6 (153) a

0.2 (2)
2.8 (31)
21.5 (242)
7.0 (79)
16.3 (183)
35.0(394)
17.2 (194) b

Employment Status
Unemployed
Employed part time
Employed full time

25.0 (278)
18.0 (200)
57.1 (635)

25.4 (286)
20.1 (226)
54.5 (613)

Insurance Status
No Insurance at all in past year
Insured for 1-6 months
Insured for 7-11 months
Insured for all 12 months of past year

12.1 (136) a
10.3 (115) a
6.8 (76)
70.8 (793) a

8.9 (100) b
6.3 (71) b
5.3 (60)
79.5 (894) b

x2 (6) = 10.354 (ns)

x2 (2) = 2.024 (ns)

x2 (3) = 23.818***

Geographical Region
Northeast
17.8 (200)
18.2 (205)
a
Midwest
15.5 (174)
22.8 (257) b
x2 (3) = 78.170***
a
b
South
54.9 (616)
38.0 (428)
a
West
11.8 (133)
20.9 (235) b
N = 2248
SD = Standard deviation
***p<.001, ns = not significant
For analyses comparing multiple categories, columns with different superscripts (a,b) differ
significantly (Bonferroni corrected)

Correlations were used to determine the extent to which ethnic centrality was related to
age, education, and income level. Pearson correlations revealed that scores on ethnic centrality
were not significantly related to age (r= -0.033, p=0.120), and were positively related to
education (r=0.066, p<0.01). Spearman’s rho indicated that ethnic centrality was negatively
related to level of income during the previous year (rs= -0.077, p<0.001).
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Hypothesis 1a-b.
Pap screening. Chi square analyses were conducted to determine whether rates of Pap
screening differed based on racial group (Table 4). There was a significant difference in lifetime
Pap screening, with White women being more likely to have ever received a Pap screening in
their lifetime. However, among women who had reported at least one lifetime screening, Black
women were more likely than White women to have received screening within the previous three
years, as well as the previous five years.
Table 4.
Differences in Pap screening based on racial group
Black Women
n (%)
a
Pap Screening, lifetime
982 (87.4)

White Women
n (%)
1026 (91.2)

X2
8.312**

Of those who had ever had a Pap screening
Pap Screening, last 3 years b
833 (84.8)
821 (80.0)
7.986**
b
Pap Screening, last 5 years
911 (92.8)
917 (89.4)
7.081**
**p<.01
a
Analysis included all participants (n=2,248)
b
Analysis included those who reported ever having received a Pap smear (n=2,008)
Abnormal Pap results. A chi square analysis was also conducted to determine whether
rates of abnormal Pap results differed based on racial group (Table 5). The analysis showed that
there was a significant difference in receipt of abnormal results overall, with 29.9 percent of
Black women and 35.7 percent of White women reporting receiving any abnormal result across
their lifetime. Specific Pap results reported by participants are present in the table, as well, and
show that the most commonly endorsed options across both racial groups were ASC-US
(Atypical Squamous Cells of Undetermined Significance) and abnormal results where specific
results of Pap screening were unknown. Black women were significantly more likely to report
receiving an abnormal result of ASC-US, while White women were significantly more likely to
report an abnormal result of HSIL (High-Grade Squamous Intraepithelial Lesion).
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Interestingly, Black women were significantly more likely to report that they never
received their Pap results from their provider, and White women were significantly more likely
to report that their Pap screening had returned an abnormal result before, but that they were not
able to recall what the specific abnormal result was.
Table 5.
Differences in abnormal Pap results based on racial group
Totals
Black Women
n (%)
n (%)
c
Any abnormal Pap result
660 (32.9)
294 (29.9)
Differences in abnormal results by race d
ASC-US
291 (44.0)
Abnormal, but unsure of result 231 (34.9)
LSIL
78 (11.8)
ASC-H
21 (3.2)
HSIL
17 (2.6)
ACG
24 (3.6)
Result of LSIL or more severe d

140 (21.2)

White Women
n (%)
366 (35.7)

X2
7.476**

153 (52.0) a
87 (29.6) a
34 (11.6)
11 (3.7)
3 (1.0) a
6 (2.0)

138 (37.5) b
144 (39.1) b
44 (12.0)
10 (2.7)
14 (3.8) b
18 (4.9)

21.279**

54 (4.8)

86 (7.6)

7.739**

Never received Pap result c
53 (2.6)
33 (3.4)
20 (1.9)
3.888*
*p<.05, **p<.01
For analyses comparing multiple categories, columns with different superscripts (a,b) differ
significantly (Bonferroni corrected)
c
Analysis included those who reported ever having a Pap smear (n=2,008)
d
Analysis included those who reported abnormal results (n=660)
Follow-up care. Further chi square analyses were used to evaluate differences in receipt
of care following abnormal Pap results (Table 6). When taking into account all abnormal results
of any severity level (i.e., lowest to highest severity included), White women were significantly
more likely than Black women to report that their providers had recommended that they obtain
some form of follow-up care after receiving their abnormal Pap results. However, if follow-up
care had been recommended by a provider, Black and White women were equally likely to report
obtaining at least some of the follow-up care that was recommended to them.
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The same pattern emerged when the abnormal results with the lowest level of severity
(i.e., ASC-US and abnormal but unsure of specific results) were removed, leaving only the more
severe abnormal results (i.e., LSIL or above) to be analyzed. In fact, even more disparate rates of
doctor recommendation were shown between the racial groups. Still, there were no significant
differences based on racial group in rates of receipt of follow-up care when higher-level
diagnostic testing (i.e., colposcopy, biopsy, LEEP, conization, cryotherapy, laser therapy, or
follow-up with a specialist) that would be appropriate for these results had been recommended
by providers.
Table 6.
Doctor recommendation of follow-up care and patient engagement after an abnormal Pap result
Totals
Black Women White Women
n (%)
n (%)
n (%)
X2
Of those who received any abnormal Pap result (n=660)
Doctor recommended follow-up care 624 (94.5)
270 (91.8)
354 (96.7)
7.543**
Of those who had a doctor recommend follow-up care (n=624)
Individual received at least some
554 (88.8)
234 (86.7)
doctor recommended follow-up care

320 (90.4)

2.138(ns)

Of those who reported a result of LSIL or more severe result (n=140)
Doctor recommended follow-up care 116 (82.9)
38 (70.4)
78 (90.7)

9.650**

Of those who had a doctor recommend follow-up care (n=116)
Individual received at least some
105 (90.5)
33 (86.8)
doctor recommended follow-up care
**p<.01

72 (92.3)

0.889(ns)

Hypotheses 2a-f.
H2a-f were tested using path models that were designed using dimensions of the Health
Belief Model to explain Pap screening behaviors. In the figure shown (figure 6), ovals indicate the
unobservable “latent” variables, which included perceived susceptibility, perceived severity,
perceived benefits, and perceived barriers. These variables were measured using multiple observed
items, as indicated in the above section detailing measures used. Rectangles indicate the observed
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variables, which were measured directly, and consist of demographic information and receipt of Pap
screening.

Figure 6. Theorized version of the Health Belief Model for H2a-f.
The baseline model was first run with the entire sample included and without considering
race as a factor, in order to determine good model fit for the sample as a whole. To ensure that the
model was also a good fit for each racial group individually, two separate but equivalent baseline
models were then run. When the full proposed HBM model predicting Pap screening during the
previous three years was run, model fit was acceptable, with a chi square=7.888 (df=1, p=0.005),
RMSEA (Root Mean Square Error of Approximation) =0.056, and a CFI (Comparative Fit
Index) =0.995. However, while this model showed good fit for White women (x2(1)=2.037,
p=0.154; RMSEA=0.031; CFI=0.999), it showed only acceptable model fit for Black women
(x2(1)=6.692, p=0.010; RMSEA=0.072; CFI=0.991). The baseline model was re-run without
nonsignificant paths emanating from demographic characteristic predictors and showed
improved overall model fit (x2(12)=17.562, p=0.130; RMSEA=0.014; CFI=.0996), as well as
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good fit for the groups of both White (x2(12)=10.127, p=0.605; RMSEA=0.000; CFI=1.000) and
Black (x2(12)=15.252, p=0.228; RMSEA=0.016; CFI=0.995) women individually.
Once the model was determined to be a good fit for both groups individually, the
configural model was run including both groups in order to establish a statistical baseline model
for invariance analyses. This model maintained good fit across both groups (x2(24)=25.375,
p=0.386; RMSEA=0.007; CFI=0.999), and still reflected a somewhat better fit for White women
compared to Black women (individual chi square contributions: 9.515 and 15.862, respectively).
The fully constrained model was then run with all remaining model paths constrained to
be equal to test for invariance between groups. Model fit was reduced, but remained acceptable
(x2(42)=110.773, p=0.000; RMSEA=0.038; CFI=0.948), and reflected worsened fit for both
groups, although fit remained worse for Black women than White women (chi square
contributions 62.628 vs 48.144, respectively). Further, the chi square difference test comparing
the constrained model to the configural model was significant, reflecting that model invariance
was not achieved (x2(18)=85.397, p=0.000).
Modification indices for the constrained model were used to remove path constraints
from the model, and indicated that paths from perceived barrier and benefit factors predicting
Pap screening, as well as covariance paths between the factors of perceived benefits and
perceived barriers, perceived susceptibility and perceived severity, perceived severity and
perceived benefits, and perceived susceptibility and perceived barriers should be relaxed and
able to vary between groups. These modifications were made and the invariance analysis was
then repeated. This model showed improved fit overall (x2(36)=42.335, p=0.216;
RMSEA=0.013; CFI=0.995), as well as for each individual group (x2 for White women=17.618,
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x2 for Black women=24.716). Model invariance was also achieved with this model
(x2(12)=16.959, p=0.151).
However, in an effort to further improve model fit among Black women, the initial
baseline model for each group was consulted to determine where other significant group
differences might lie. Paths that were nonsignificant for either White or Black women in this
baseline model were relaxed so that they were able to vary between groups, and the model was
re-run. Nonsignificant paths only among White women included the ones between insurance
status and perceived severity, as well as perceived susceptibility and Pap screening; while the
nonsignificant paths among only Black women included those between education predicting
perceived susceptibility, as well as age, federal poverty level (FPL) standing, and perceived
benefits predicting engagement in Pap screening.
Model invariance remained in this final model (x2(6)=4.059, p=0.669), and model fit was
further improved overall (x2(30)=29.435, p=0.495; RMSEA=0.000; CFI=1.000), and for each
group individually (x2 for White women=11.663, x2 for Black women=17.772). The r-square
values showed that this final model explained 25.6% and 20.4% of the variance in Pap screening
behavior during the previous three years for White and Black women, respectively. As depicted
in figures 7.1-7.3, the model further showed that while paths from insurance status, perceived
barriers, and perceived susceptibility predicting Pap screening, along with paths from age and
insurance status predicting perceived barriers, and insurance status predicting perceived benefits
were significant and able to be constrained to be equal across groups, many others varied.
Paths from age, FPL standing, and perceived benefits predicting Pap screening were not
significant for Black women, but had influence for White women. A similar pattern emerged for
the path between education predicting perceptions of susceptibility to cervical cancer.
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Conversely, the path from perceived susceptibility predicting Pap screening was not significant
for White women, but had influence for Black women. The same pattern emerged for the path
between insurance status predicting perceived severity of cervical cancer, and although the path
between age predicting perceived severity was significant among White women, it remained
more influential for Black women.
Hypothesis Outcomes. Partial support was found for this collection of hypotheses. H2a
found minimal support. For White women, age was negatively related to Pap screening, meaning
that as age increased engagement in Pap screening decreased, and SES was positively related to
Pap screening, such that as SES increased engagement in Pap screening increased, as well.
However, age and education were not significant predictors of Pap screening receipt among
Black women, and education was not a significant predictor of screening for either racial group,
resulting in a lack of full support for this hypothesis.
H2b was supported, as insurance status was negatively related to perceptions of barriers
to obtaining Pap screening, and this relationship was more influential among Black women. For
both groups, this result indicates that as duration of insurance coverage during the previous year
increased, the perception of barriers to obtaining screening decreased.
H2c was partially supported, with perceptions of susceptibility to cervical cancer being
positively related to Pap screening, but only among Black women. Perceptions of cervical cancer
severity were positively related to Pap screening behavior among both racial groups and
reflected a stronger influence among Black women, which provided complete support for H2d.
Partial support was also attained for H2e. Perceptions of barriers to screening were
negatively related to engagement in Pap screening. Although present results indicated a slightly
stronger relationship value for Black women, the influence of this path was closer to being equal
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across the racial groups. H2f was supported, though, as perceptions of benefits to Pap screening
positively predicted engagement in Pap screening, and this relationship was only significant
among White women.
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Figure 7.1. Path model showing the final invariant model for H2a-f. Line arrows represent significant constrained paths that did not
show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001, ns = not significant
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Figure 7.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001
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Figure 7.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001
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Hypotheses 3a-g.
H3a-g were tested using path models that were designed using dimensions of the Health
Belief Model to explain follow-up service use behaviors following receipt of an abnormal Pap result.
This model is an extension of the path model used to evaluate H2a-f, and includes the addition of the
variable of severity of an abnormal Pap result as conveyed by a medical provider. In the figure
shown (figure 8), ovals indicate the unobservable “latent” variables, which consist of the severity of
abnormal Pap results as relayed by a medical provider, perceived susceptibility, perceived severity,
perceived benefits, and perceived barriers. These variables were measured using multiple observed
items, as indicated in the above section detailing measures used. The rectangles indicate the observed
variables, which were measured directly, and consist of demographic information and receipt of
recommended follow-up care.

Figure 8. Theorized version of the Health Belief Model for H3a-g.
The theorized baseline model was first run with the entire sample of those who had reported
ever receiving an abnormal Pap result included (n=660) and without considering race as a factor, in
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order to determine good model fit for the sample as a whole. To ensure that the model was also a
good fit for each racial group individually, two separate but equivalent baseline models were then
run. When the full proposed HBM model predicting engagement in follow-up care was run, model fit
was acceptable (x2(3)=14.283, p=0.003; RMSEA=0.076; CFI=0.955). While this model showed a
good fit for Black women (x2(3)=4.142, p=0.247; RMSEA=0.036; CFI=0.988), it showed very
poor fit for White women (x2(3)=13.874, p=0.003; RMSEA=0.100; CFI=0.933).
The baseline model was re-run without paths that were nonsignificant among both groups
(i.e., paths from insurance status predicting perceived susceptibility, perceived severity, and
perceived benefits; and paths from FPL predicting perceived susceptibility, severity, benefits,
barriers, and the receipt of follow-up care) and showed improved overall model fit
(x2(6)=15.053, p=0.020; RMSEA=0.048; CFI=0.961), as well as good fit among both Black
(x2(6)= 7.828, p=0.251; RMSEA=0.032; CFI=0.978) and White (x2(6)=13.402, p=0.371;
RMSEA=0.058; CFI=0.951) women.
After this model was determined to show good fit among both groups individually, the
configural model was run including both groups to establish a statistical baseline model for
invariance analyses. This model maintained good fit across both groups (x2(12)=21.352,
p=0.455; RMSEA=0.049; CFI=0.961), although it did reflect better fit for Black women
compared to White women (individual chi square contributions: 7.678 vs 13.674, respectively).
The fully constrained model was then run with all remaining model paths constrained to
be equal in order to test for invariance between groups. Model fit was slightly reduced, but
remained acceptable (x2(36)=58.800, p=0.010; RMSEA=0.043; CFI=0.906), and reflected
worsened fit that was roughly equal across both groups (x2 for Black women=29.244; x2 for
White women=29.256). Further, the chi square difference test comparing the constrained model
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to the configural model was significant, reflecting that model invariance was not achieved
(x2(24)=37.148, p=0.042).
Modification indices for the constrained model were used to determine that the addition
of paths using severity of the result as relayed by a doctor to predict perceived benefits and
barriers to follow-up care would improve model fit for White women. These paths were added to
the model, were relaxed, and the invariance analysis was repeated. This model showed improved
fit overall (x2(32)=44.708, p=0.067; RMSEA=0.035; CFI=0.947), and did show improved fit for
White women (x2=18.341), although fit was not drastically improved for Black women
(x2=26.367). Model invariance was achieved through these changes (x2(20)=23.356, p=0.272).
In an effort to improve model fit for Black women, the initial baseline and constrained
models were consulted to determine where other significant group differences might lie. Paths
that were nonsignificant for either White or Black women (but not among both groups) were
relaxed (i.e., paths from age predicting perceived susceptibility to cervical cancer and receipt of
follow-up care; paths from education predicting perceived susceptibility, severity, and benefits,
as well as receipt of follow-up care; a path from insurance status predicting perceived barriers to
follow-up care; paths from perceived susceptibility to cervical cancer and benefits of follow-up
care predicting receipt of follow-up care; and a path from severity of abnormal results as
conveyed by a medical provider predicting perceptions of severity of cervical cancer).
Not only was overall model fit improved (x2(23)=21.269, p=0.565; RMSEA=0.000;
CFI=1.000), but model fit was stronger than in the original configural model, and showed
improved fit for each group individually (x2 for Black women=12.674; x2 for White
women=8.595). The r-square values showed that that this final model explained 17.2% and
20.2% of the variance in follow-up service use after receiving an abnormal Pap result for Black
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and White women, respectively. As depicted in figures 9.1-9.3, only 10 of the 24 originally
hypothesized paths remained in the final model. Six of these paths were able to be constrained to
be equal across groups (i.e., paths from age predicting perceptions of severity of cervical cancer;
insurance status predicting perceived barriers to follow-up care; insurance status and perceived
barriers to follow-up care predicting receipt of follow-up care; and severity of results as
conveyed by a medical provider predicting perceived susceptibility to cervical cancer.
The model additionally required that the four remaining paths be relaxed and able to vary
between groups, and that two additional paths be added to the model. The final invariant model
thus had 10 significant paths. The negative path from education level predicting perceived
susceptibility to cervical cancer, as well as the positive path from perceived benefits predicting
receipt of follow-up care were significant for White women but not for Black women. The added
paths from severity of an abnormal Pap result as conveyed by a medical provider positively
predicting perceived barriers and negatively predicting perceived benefits of follow-up care were
also significant for White women but not among Black women. Conversely, positive paths from
severity of an abnormal Pap result as conveyed by a medical provider predicting perceptions of
severity of cervical cancer and from perceived susceptibility to cervical cancer predicting receipt
of follow-up care were only significant for Black women.
Hypothesis Outcomes. Partial support was found for this collection of hypotheses, as
well. H3a was not supported, as age, education, and SES were not significantly related to
obtaining follow-up care for either racial group. However, age was found to significantly predict
perceptions of cervical cancer severity and benefits of follow-up care for both racial groups, such
that perceptions of cervical cancer severity and benefits to obtaining follow-up care decreased as
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age increased. It was further found that education significantly predicted perceptions of cervical
cancer susceptibility for White women, with perceptions decreasing as education level increased.
H3b was partially supported, as insurance status was found to be negatively related to
perceptions of barriers to follow-up care, and positively related to engagement in follow-up care
after an abnormal Pap result. These results showed that as duration of insurance status during the
previous year increased, perceptions of barriers to follow-up care decreased, and engagement in
follow-up care increased. However, the influences of these relationships were roughly equal
between racial groups.
Full support was found for H3c, with severity of an abnormal Pap result as conveyed by a
medical provider positively predicting perceptions of susceptibility to cervical cancer for both
racial groups. Results reflected a positive relationship, such that as the conveyed severity of
abnormal Pap results increased, perceptions of susceptibility to cervical cancer increased, as
well. Conversely, severity as conveyed by a medical provider only positively predicted
perceptions of cervical cancer severity among Black women, resulting in a lack of full support
for H3d.
Partial support was found for H3e. Perceptions of barriers to receiving follow-up care
was negatively related to obtaining follow-up care for both racial groups. However, this
relationship was not found to be more influential among Black women, as this path was
constrained to be roughly equal across racial groups. H3f received support, with perceptions of
benefits to receiving follow-up care after an abnormal Pap result being significantly, positively
related to obtaining follow-up care among White – but not Black – women.
Finally, only partial support was found for H3g. The influence of perceived benefits of
follow-up care predicting follow-up care utilization (which was only significant for White
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women) was stronger than that of the prediction of perceived benefits on Pap screening
utilization in H2 (β=.287 vs β=.144, respectively), thus providing support for the hypothesis.
However, although perception of barriers to follow-up care significantly, negatively predicted
follow-up care utilization for both racial groups, the influence of perceived barriers predicting
Pap screening utilization (H2) was much stronger for both groups, reflecting a β=0.160 decrease
between the models for White women and a β=0.187 decrease for Black women between the two
models.
Additionally, although not originally part of the hypothesized model, modification
indices suggested that two paths be added to improve the model. These newly added paths from
severity of an abnormal Pap result as conveyed by a medical provider positively predicting
perceived barriers and negatively predicting perceived benefits to obtaining follow-up care were
significant for White women but not among Black women.
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Figure 9.1. Path model showing the final invariant model for H3a-g. Line arrows represent significant constrained paths that did not
show moderation by race. Dashed arrows represent paths that were part of the original theoretical model and were relaxed/ moderated
by race. Bolded dashed arrows represent paths that were later added to the theoretical model and relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001, ns = not significant
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Figure 9.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were part of the original theoretical model and were
relaxed/ moderated by race. Bolded dashed arrows represent paths that were later added to the theoretical model and relaxed/
moderated by race.
*p<.05, **p<.01, ***p<.001
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Figure 9.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001
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Hypotheses 4a-b.
To test hypotheses 4a-b, four moderation analyses were run. Product terms were created
from the independent and moderator variables for each analysis. The first two analyses for H4a
evaluated the hypothesized influence of ethnic centrality on the relation between perceived
susceptibility to cervical cancer and receipt of recommended follow-up care. For both Black and
White women, perceived susceptibility was not significantly related to receipt of follow-up care
(β=0.153, p=0.164 vs. β= -0.184, p=0.084, respectively). Further, ethnic centrality was neither a
significant moderator for this relationship (β=0.232, p=0.067 vs. β=0.033, p=0.732), nor a
significant predictor for receipt of follow-up care (β=0.138, p=0.229 vs. β= -0.097, p=0.383) for
either racial group.
The second set of analyses for H4b evaluated the hypothesized influence of ethnic
centrality on the relation between perceived severity of cervical cancer and receipt of
recommended follow-up care. The same pattern emerged. Again, for both Black and White
women, perceived severity was not significantly related to receipt of follow-up care (β=0.119,
p=0.517 vs. β=0.084, p=0.674, respectively). Ethnic centrality was also not a significant
moderator between the variables (β=0.132, p=0.283 vs. β= -0.267, p=0.087), and it was not a
significant predictor of receipt of follow-up care on its own (β=0.124, p=0.545 vs. β=0.366,
p=0.134).
Although the moderations were not significant for either group, interesting findings did
emerge. Results from these analyses indicated that ethnic centrality was significantly related to
perceived susceptibility (βBlack= -0.616, p<0.001 and βWhite= -0.735, p<0.001) and perceived
severity (βBlack= -0.908, p<0.001 and βWhite= -0.927, p<0.001) for both groups.

63
Hypothesis 4c.
Hypothesis 4c was tested using path models that were an extension of those used to test
H3a-g. The paths from the final invariant model used in H3a-g were used as a baseline to
construct the model tested in H4c. Although the moderations in H4a-b were not significant in
predicting follow-up service use behaviors, ethnic centrality was shown to be significantly
related to perceptions of both cervical cancer susceptibility and severity. As a result of this
finding, ethnic centrality was not added into the final model as a moderator, and was instead
entered as a predictor of both perceived susceptibility and perceived severity. The final model is
shown in figure 10, where ovals indicate the unobservable “latent” variables, including the
severity of abnormal Pap results as relayed by a medical provider, perceived susceptibility, perceived
severity, perceived threat, perceived benefits, perceived barriers, and ethnic centrality. These
variables were measured using multiple observed items, as indicated in the above section detailing
measures used. Similar to the previously tested models, the rectangles indicate the observed
variables, which were measured directly, and consist of demographic information and receipt of
recommended follow-up care.
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Figure 10. Theorized version of the Health Belief Model for H4c (modified to include
significant paths from the final invariant model of H3).
As in previous analyses, the theorized baseline model from figure 10 was first run with the
entire sample of those who had reported ever receiving an abnormal Pap result included (n=660) and
without considering race as a factor, in order to determine good model fit for the sample as a whole.
To ensure that the model was also a good fit for each racial group individually, two separate but
equivalent baseline models were then run. When the full proposed HBM model predicting
engagement in recommended follow-up care was run, model fit was good (x2(6)=10.469, p=0.106;
RMSEA=0.034; CFI=0.981). This model showed acceptable fit for Black women (x2(6)=12.571,
p=0.050; RMSEA=0.061; CFI=0.927), and showed good fit for White women (x2(6)=6.945,
p=0.326; RMSEA=0.021; CFI=0.994). The configural model was then run including both groups
to establish a baseline model for invariance analyses. This model maintained good fit across both
groups (x2(12)=19.503, p=0.077; RMSEA=0.043; CFI=0.969), although it reflected better fit for
White women compared to Black women (individual chi square contributions: 6.836 and 12.667,
respectively).
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The fully constrained model was then run with all model paths constrained to be equal in
order to test for invariance between groups. Model fit was slightly reduced, but remained good
(x2(41)=61.370, p=0.021; RMSEA=0.039; CFI=0.917), and reflected worsened fit for both
groups, although fit remained worse for Black women (x2 for White women= 24.226; x2 for
Black women= 37.144). Further, the chi square difference test comparing the constrained model
to the configural model was significant, reflecting that model invariance was not achieved with
the fully constrained model (x2(29)=41.867, p=0.048).
The constrained model showed no significant modification indices through which the
model could be improved. Therefore, in an effort to improve model fit for both racial groups, and
among Black women in particular, the initial baseline and constrained models were consulted to
determine where other significant group differences might lie. Paths that were nonsignificant for
either White or Black were relaxed (i.e., paths from: age predicting perceived benefits to followup care; education predicting perceived susceptibility to cervical cancer; severity of the abnormal
Pap result as conveyed by a medical provider predicting both perceived severity of cervical
cancer and benefits of follow-up care; perceived susceptibility to cervical cancer and benefits of
follow-up care predicting use of follow-up care; and ethnic centrality predicting perceived
severity of cervical cancer).
Model invariance was achieved in this model (x2(20)=14.705, p=0.793). Model fit was
improved overall (x2(32)=34.208, p=0.362; RMSEA=0.014; CFI=0.991), and was improved for
each group individually (x2 for Black women=21.139; x2 for White women=13.069). However, in
an effort to further improve model fit for Black women, one additional modification was made to
the model. While modification indices and baseline models did not provide any additional insight
into potential improvements to the model, after consulting previous literature and theory, a path
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from ethnic centrality predicting perceived benefits of follow-up care was added and relaxed to
vary across groups. This addition was based on literature showing that some Black women felt
that cervical care could preserve their personal health and allow them to care for others, while
others delayed care as a result of the “Strong Black Woman” schema, suggesting that they were
expected to sacrifice their own well-being to care for others around them (Bellinger et al., 2015).
These findings thus suggested that ethnic centrality may have an influence on the perception of
potential benefits to obtaining follow-up cervical care services.
This final model showed improved overall model fit (x2(32)=23.637, p=0.857;
RMSEA=0.000; CFI=1.000), as well as improved model fit for each group (x2 for Black
women=13.512; x2 for White women=10.125). The r-square values showed that that this final
model explained 17.7% and 20.1% of the variance in follow-up service use after receiving an
abnormal Pap result for Black and White women, respectively.
As depicted in figures 11.1-11.3, 14 of the 23 hypothesized paths remained in the final
model. Seven of these paths were able to be constrained to be equal across groups, and seven of
the paths had to be relaxed and allowed to vary between groups. An additional path was later
added to the model and was constrained to be equal, resulting in 15 significant paths in the final
invariant model.
Five of the constrained paths were the same as those present in the final invariant model
for H3 (i.e., negatively related paths from age predicting perceptions of cervical cancer severity,
insurance status predicting perceptions of barriers to follow-up care; and perceived barriers
negatively predicting receipt of follow-up care; as well as positively related paths from insurance
status predicting receipt of follow-up care; and the added path that was not present in the
originally hypothesized model from severity of abnormal Pap results as conveyed by a medical
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provider predicting perceptions of susceptibility to cervical cancer). In the present model, a
previously relaxed path emanating from severity of abnormal Pap results as conveyed by a
medical provider positively predicting perceptions of barriers to follow-up care was able to be
constrained to be equal across groups. Additionally, two new positively related paths from age
predicting engagement in follow-up care and ethnic centrality predicting perception of benefits to
follow-up care were added to the model and able to be constrained to be equal across racial
groups.
Five of the seven relaxed paths reflected the same paths seen in the final invariant model
for H3. Three of these paths (i.e., two negatively related paths from education predicting
perceptions of susceptibility to cervical cancer, and severity of abnormal Pap results as conveyed
by a medical provider predicting perceived benefits to follow-up care; as well as one positively
related path from perceived benefits predicting receipt of follow-up care) were significant for
White women, while they were not significant for Black women. The other two paths (i.e.,
positively related paths from severity of abnormal Pap results as conveyed by a medical provider
predicting perceptions of cervical cancer severity, and perceptions of susceptibility to cervical
cancer predicting engagement in follow-up care) were significant among Black, but not White,
women.
The two remaining relaxed paths differed from the final invariant model present in H3. A
path from age predicting perceptions of benefits to follow-up care that had previously been
constrained to be equal in the final invariant model for H3 was relaxed in the current model, and
represented a significant negative relationship only among White women. Additionally, the
theorized path from ethnic centrality predicting perceptions of cervical cancer severity was
unique to hypothesis 4, and showed a significant positive relationship among Black women only.
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Hypothesis Outcomes. H4a and b were not supported, as all moderation analyses were
nonsignificant. However, although ethnic centrality did not directly predict attainment of followup care or moderate the relationships between perceived cervical cancer susceptibility or severity
and attainment of follow-up care, this variable did emerge as a significant predictor of both
perceived susceptibility and perceived severity. Thus, ethnic centrality was added into later path
models as a predictor of both of these variables.
Using the reconceptualized model that positioned ethnic centrality as a predictor rather
than a moderator, H4c received little support. Although ethnic centrality did not significantly
predict perceptions of susceptibility to cervical cancer for either racial group in the full model, it
did predict perceptions of cervical cancer severity among Black women. However, this
relationship showed that as feelings of ethnic centrality increased, perceptions of the severity of
cervical cancer increased, rather than decreased.
An additional finding that was not originally hypothesized was that of ethnic centrality
positively predicting the perception of benefits to obtaining follow-up care for both racial groups.
Although this relationship was more influential among Black women, higher levels of ethnic
centrality were related to increased perceptions of benefits to obtaining follow-up care for both
racial groups.
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Figure 11.1. Solid line arrows represent significant constrained paths that did not show moderation by race. Dashed arrows represent
paths that were part of the original theoretical model and were relaxed/ moderated by race. Bolded line arrows represent constrained
paths that were later added to the theoretical model and did not show moderation by race. Bolded dashed arrows represent paths that
were later added to the theoretical model and relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001, ns = not significant
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Figure 11.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were part of the original theoretical model and were
relaxed/ moderated by race. Bolded line arrows represent significant constrained paths that were not moderated by race. Bolded
dashed arrows represent paths that were later added to the theoretical model and relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001
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Figure 11.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race. Bolded line arrows
represent constrained paths that were later added to the theoretical model and did not show moderation by race.
*p<.05, **p<.01, ***p<.001
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Exploratory Analyses.
Exploratory analyses conducted as part of hypothesis 1 revealed that: (1) there were
significant racial disparities in the reported rates of doctor recommendation to obtain follow-up care
after receiving an abnormal Pap result, with White women being significantly more likely than Black
women to report that their provider recommended follow-up care, and (2) the significant racial
disparity found in rates of receipt of follow-up care were eliminated once receiving a doctor’s
recommendation to obtain follow-up care was accounted for in analyses. As a result, another set of
exploratory analyses were used to evaluate the role of provider recommendation to obtain follow-up
care, if any, when added to the model tested in hypothesis 4c. The theoretical model tested is shown
in figure 12, where ovals indicate the unobservable “latent” variables, and rectangles indicate directly
measured “observable” variables, as in previous hypotheses.

Figure 12. Theorized version of the Health Belief Model for exploratory analyses. This model
reflects the model theorized for H4c, with the addition of doctor recommendation to obtain
follow-up care.
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As in the previous models, the theorized baseline model from figure 12 was first run with the
entire sample of those who had reported ever receiving an abnormal Pap result included (n=660) and
without considering race as a factor, in order to determine good model fit for the sample as a whole.
To ensure that the model was also a good fit for each racial group individually, two separate but
equivalent baseline models were then run. When the full proposed HBM model predicting
engagement in recommended follow-up care was run, model fit was good (x2(5)=6.701, p=0.244;
RMSEA=0.023; CFI=0.995). This model showed good fit for both Black (x2(5)=5.221, p=0.390;
RMSEA=0.012; CFI=0.998) and White (x2(5)=3.863, p=0.569; RMSEA=0.000; CFI=1.000)
women individually, as well.
The configural model was then run including both groups to establish a baseline model
for invariance analyses. This model maintained good fit across both groups (x2(10)=9.066,
p=0.526; RMSEA=0.000; CFI=1.000), and reflected only slightly better fit for White women
compared to Black women (individual chi square contributions: 3.805 and 5.262, respectively).
Next, the fully constrained model was run with all model paths constrained to be equal, in
order to test for invariance between groups. Model fit was reduced, but remained good
(x2(45)=76.160, p=0.003; RMSEA=0.046; CFI=0.904), and reflected worsened fit for both
groups (x2 for White women=35.203; x2 for Black women=40.957). Further, the chi square
difference test comparing the constrained model to the configural model was significant,
reflecting that model invariance was not achieved with the configural model (x2(35)=67.094,
p=0.001).
Modification indices from the constrained model suggested that the path from doctor
recommendation predicting perceived benefits be relaxed. This path, as well as some others that
were shown in the initial baseline and constrained models to be nonsignificant for either White
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or Black women, but not for both groups, (i.e., paths from age predicting perceived susceptibility
to cervical cancer and benefits of follow-up care; education predicting perceived benefits;
severity of abnormal Pap results as conveyed by a medical provider and ethnic centrality
predicting perceived severity of cervical cancer and benefits of follow-up care; doctor
recommendation to obtain follow-up care predicting perceived barriers to follow-up care; and
perceived susceptibility to cervical cancer predicting receipt of follow-up care) were relaxed, and
the model was re-run.
Model invariance was achieved in this model (x2(24)=19.855, p=0.705). Model fit was
improved overall (x2(34)=28.921, p=0.715; RMSEA=0.000; CFI=1.000), and showed
improvement for each group individually (x2 for Black women=16.554; x2 for White
women=12.368). R-square values showed that that this final model explained 47.4% and 36.0%
of the variance in follow-up service use after receiving an abnormal Pap result for Black and
White women, respectively.
As depicted in figures 13.1-13.3, 17 of the 29 originally hypothesized paths remained in
the final model. Eight of these paths were able to remain constrained to be equal across groups,
and nine of the paths had to be relaxed and able to vary between groups. Constrained paths for
the current invariant model include seven of the same constrained paths present in the final
invariant model for H4c (i.e., three negatively related paths from age predicting perceptions of
cervical cancer severity; insurance status predicting perceived barriers to obtaining follow-up
care; and perceived barriers predicting receipt of follow-up care; as well as four positively
related paths from insurance status predicting receipt of follow-up care; severity of abnormal Pap
results as conveyed by a medical provider predicting perceptions of susceptibility to cervical
cancer and barriers to follow-up care; and ethnic centrality predicting perceived benefits of
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obtaining follow-up care). The theorized path from doctor recommendation positively predicting
receipt of follow-up care was unique to this exploratory analysis, and was additionally able to be
constrained as equal across both racial groups.
Relaxed paths for the current model included seven paths that were present in the final
invariant model for H4c, as well. Four of these paths (i.e., three negatively related paths from age
predicting perceptions of benefits to follow-up care; education predicting perceptions of
susceptibility to cervical cancer, and severity of abnormal Pap results as conveyed by a medical
provider predicting perceived benefits to follow-up care, as well as one positive path from
perceived benefits predicting receipt of follow-up care) remained significant only among White
women, while three of these paths (i.e., positively related paths from severity of abnormal Pap
results as conveyed by a medical provider and ethnic centrality predicting perceptions of
severity of cervical cancer; and perceptions of susceptibility to cervical cancer predicting receipt
of follow-up care) remained significant only among Black women.
For the present analysis, two new paths from doctor recommendation to obtain follow-up
care positively predicting perception of benefits and negatively predicting perception of barriers
to obtaining follow-up care were added to the model. These paths were relaxed, and were found
only to be significant among White women.
Exploratory Outcomes. Although doctor recommendation to obtain follow-up care after
receiving an abnormal Pap result was not initially included as a variable in the hypotheses for
this project, analyses conducted early on in the project indicated that it was an important variable
to consider in attempting to model follow-up care decision-making processes for both groups of
women. For White women, doctor recommendation was related to increased perceptions of
benefits to obtaining follow-up care and decreased perceptions of barriers to obtaining follow-up
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care. Although the influence was stronger among Black women, doctor recommendation was
also related to an increased likelihood of obtaining follow-up care after an abnormal Pap result
was received for both groups. This path additionally represented the strongest variable
relationship in the model across both racial groups. The inclusion of these three variable paths
into the model improved the overall amount of variance accounted for in receipt of follow-up
care by 29.7 and 15.9 percentage points for Black and White women, respectively.
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Figure 13.1. Path model showing the final invariant model for the exploratory hypothesis. Solid line arrows represent significant
constrained paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001, ns = not significant
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Figure 13.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001
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Figure 13.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.
*p<.05, **p<.01, ***p<.001
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Discussion
The primary goal of the present research was to address significant gaps in the literature
regarding disparities in cervical cancer diagnosis and mortality among Black women. Because
Pap screening behavior has been extensively assessed without major improvements in disparate
rates of diagnosis and mortality among Black women, this project pivots the research frame of
interest to receipt of follow-up care after receiving an abnormal Pap result. Although decisionmaking and healthcare-seeking behaviors related to Pap screening among Black women have
been studied and prior work has determined that Black women are less likely than other racial
groups to receive follow-up care (Fleming et al., 2014; Sharma et al., 2012), specific factors
influencing decisions to receive cervical cancer follow-up care among this population had not
been formally studied.
This is the first study to use path modeling and model invariance analyses to provide a
thorough evaluation of how various factors may be associated with Black women’s decisionmaking processes related to obtaining cervical cancer screening and necessary follow-up care
after an abnormal result. This method of analysis provides the ability to thoroughly examine 1)
how various factors as defined by previous literature and operationalized through the HBM may
be associated with Pap screening behavior, as well as receipt of recommended follow-up care
following receipt of abnormal Pap results, 2) whether the aspects of care serving as significant
factors in the path model assessing associations with Pap screening behavior for each racial
group are similarly associated with receipt of recommended follow-up care, 3) whether the
factors significantly influencing the decision-making processes for receipt of both types of
cervical cancer care differ between Black and White women, and 4) whether ethnic centrality
influences the overall cervical cancer follow-up care decision-making process for Black women.
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Hypotheses 1a-b.
Hypotheses 1a and b examined differences in health service use related to cervical cancer
prevention and treatment based on racial group. Across racial groups, the majority of participants
reported having ever received a Pap smear, as well as receiving a Pap smear within the last 3
years. Findings from hypothesis 1a show that White women were more likely to report ever
having received Pap screening in their lifetime. However, results also showed that among those
who reported having ever received a Pap screening, Black women were more likely to have
received screening within the last 3 to 5 years, as is currently recommended by medical
guidelines. These findings do not provide direct support for existing statistics showing that Black
women are obtaining Pap screening at equal rates to those of White women (ACS, 2016).
Instead, these findings may suggest that Black women are still experiencing disparities in
cervical cancer screening initiation, and further suggest that once Black women do begin
screening, they are more likely to continue receiving this preventive care at medically
recommended intervals.
These findings may provide support for the various programs and media campaigns that
have been aimed at increasing rates of Pap screening among Black women, as it is possible that
these programs have contributed to the rates of continued care that are seen here. Results also
suggest that these program efforts would be particularly beneficial when aimed toward
increasing initiation of Pap screening among Black women. In line with previous literature
(Johnson et al., 2016; Tracy et al., 2013), Black women of all ages may additionally benefit from
their medical providers engaging in ongoing conversations and education about cervical cancer
health and the importance of initiating and continuing preventive screening.
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While initial analyses for hypothesis 1b revealed racial disparities in follow-up care
service use after receiving an abnormal Pap result, with White women being more likely to
obtain care, further examination revealed more nuanced relationships. Additional analyses run to
compare instances of doctor recommendation of follow-up diagnostic testing or treatment
services between racial groups showed that White women were more likely than Black women to
report that their provider had recommended obtaining follow-up services. This result was found
among those who had received an abnormal Pap result of any severity level (96.7% of White
women vs. 91.8% of Black women), and was even further exaggerated when evaluating only
those who had received an abnormal Pap result of higher severity (i.e., where those reporting
ASC-US and unknown abnormal results were excluded from analysis; 90.7% of White women
vs. 70.4% of Black women). Interestingly, when looking only at those women who reported
receiving doctor recommendations for follow-up care, Black and White women were equally
likely to have obtained the care that their provider recommended.
These results suggest that doctor recommendation is particularly influential when
evaluating racial disparities in follow-up care receipt. Results may indicate that some medical
providers are not appropriately recommending follow-up care, or that they are not effectively
communicating information about abnormal Pap results and appropriate next steps with their
Black patients. The latter possibility is supported in prior work that has shown confusion about
or trouble remembering providers’ statements about their abnormal Pap results and necessary
follow-up care (Bellinger et al., 2015). This supports previous work showing that Black women
are less likely to have access to high quality care, which is likely to subsequently influence the
quality and appropriateness of treatment following the receipt of abnormal Pap results (Hicks et
al., 2006; Weragoda et al., 2016).
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These findings may also reflect underlying racial differences in where health services are
being obtained, as other work has reported that Black women are more likely to seek their
cervical cancer care from primary care providers or emergency departments, while White women
are more likely to seek care from gynecologists (Waknine, 2005). It is probable that providers
who are reproductive health specialists, such as gynecologists, will be more familiar with
medical guidelines and recommendations following abnormal Pap results than providers who are
primarily focused in general medicine. If providers are not following medical guidelines for
handling abnormal Pap results and follow-up care, additional training for providers that educates
about these medical guidelines and provides a focus on effective communication of screening
results and suggested follow-up tests or treatment could be beneficial for both medical providers
and patients in improving health outcomes.
Hypotheses 2a-f.
The second group of hypotheses examined the utility of the HBM in predicting Pap
screening behavior for Black and White women. Previous work has studied some of the factors
of the HBM individually to determine how they relate to cervical cancer disparities and
screening behavior (Bellinger et al., 2015; Parrish, 2016; Strohl et al., 2015; Wong et al., 2013;
Wong et al., 2014). The present study sought to evaluate how each of the HBM factors related to
Pap screening behavior, and to determine whether different facets of the model were
differentially influential for Black versus White women (i.e., whether the HBM factors that were
most influential in decision-making were different for Black women versus White women).
Present findings indicate some similarities between Black and White women on the impact of
HBM factors, as well as some important differences.
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Similarities found between the groups include education not being significantly related to
Pap screening, as well as insurance status being positively and the perception of barrier to
screening being negatively related to screening behavior. In addition to being significant across
both racial groups, the relationship between perceived barriers predicting engagement in Pap
screening was also the strongest relationship present in the model for both groups, while the
relationship between insurance status and perceived barriers was the second strongest.
These findings support existing research showing that lack of insurance coverage,
inadequate insurance coverage, and the presence of other barriers (e.g., being able to take time
off from work, securing childcare in order to go to a doctor) are related to lower rates of
preventive service use among women, regardless of racial group (Bellinger et al., 2015; Kaiser
Family Foundation [KFF], 2013). Similarly, a nationally representative study not limited to
women showed that only 33% of uninsured individuals – versus 67% of those with Medicaid and
74% of those privately insured – received preventive screenings (Garfield et al., 2014). Because
women are more likely to experience gaps in health insurance coverage due to their increased
likelihood of being employed part-time, being covered as a dependent on a partner’s plan, and
being of lower SES (KFF, 2013), insurance coverage is a particularly influential factor in
preventive screening behavior. Considering that Kaiser Family Foundation (2013) has found that
53% of uninsured women resided below 138% of the FPL, these findings will maintain their
importance as some states continue in their refusal to expand Medicaid coverage.
Differences in HBM structure between Black and White women include the following:
perceptions of personal susceptibility to cervical cancer were only influential in predicting Pap
screening for Black women; perceptions of benefits to receiving Pap screening were only
significant in predicting screening for White women; and while perceptions of cervical cancer
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severity significantly predicted screening behavior for those in both racial groups, this
relationship was more influential for Black women. Previous work has highlighted lack of
knowledge among Black women related to cervical cancer, their increased risk for mortality
from cervical cancer, and how to prevent it (Parrish, 2016). Present findings that perceptions of
susceptibility to cervical cancer and severity are influential for Black women, while benefits of
screening are not, may add a degree of nuance to this work, as well as to research and
community programming focused on promoting such education among Black women in efforts
to increase screening (Strohl et al., 2015).
Hypotheses 3a-g.
The third set of hypotheses built upon the HBM constructed in hypotheses 2a-f to analyze
the role of these same factors in predicting engagement in follow-up care after receiving an
abnormal Pap result. This model included the addition of a factor representing the severity of the
abnormal Pap result received as conveyed by a medical provider. Although it had yet to be
formally researched, prior work suggested that disparities in cervical cancer diagnosis and
mortality rates between Black and White women were likely due to disparities in follow-up care
attainment and/ or quality between the groups (Bernard et al., 2012; Brandt et al., 2006; DeSantis
et al., 2013; Horner et al., 2011; Weragoda et al., 2016). Additional work has also shown that
Black women obtain follow-up care at the lowest rates of any racial group (Fleming et al., 2014;
Sharma et al., 2012). Because prior work showed that certain experiences and motivations
related to Pap screening behaviors are different for Black versus White women, it was
hypothesized that the decision-making process for obtaining follow-up care after receiving an
abnormal Pap result would also differ by racial group. Due to previous work indicating that
doctor recommendation and effective communication between providers and patients (Ackerson,
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2010; Bazargan et al., 2004) are important influences in obtaining Pap care (Johnson et al., 2016;
Tracy et al., 2013), it was additionally hypothesized that the severity of Pap results as conveyed
by a medical provider would be an influential factor in this decision-making process, in that if
would increase perceptions of cervical cancer susceptibility and severity.
Partial support was found for this collection of hypotheses, and present results noted
many similarities and differences between racial groups. For both groups, perceptions of cervical
cancer severity and benefits to obtaining follow-up care decreased as age increased. This result
may be related to previous work that has found that some women do not feel they need follow-up
care because they believe that if something were wrong with their cervix then they would notice
or feel it (Ackerson, 2010; Bellinger et al., 2015). This feeling of knowing what is normal or
abnormal for one’s body and reproductive system are likely to increase with age and life
experience. Regardless of the reasoning, though, these results may point to increased need for
campaigns aimed at educating older women about the influences of cervical cancer and the
benefits of obtaining follow-up care.
Another similarity between the groups was the finding that increases in duration of health
insurance coverage for the previous year were related to decreased perceptions of barriers to
follow-up care, as well as an increased likelihood of obtaining follow-up care after receiving an
abnormal Pap result. These findings support previous literature outlined in the discussion of H1
outcomes showing lack of health insurance as a barrier to receiving various types of needed
healthcare services (KFF, 2013), and echo prior work noting the importance of access to quality
health insurance to cover medical costs (Garfield et al., 2014; Sung, Alema-Mensah, &
Blumenthal, 2002).
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Perceptions of barriers to follow-up testing were equally influential across racial groups,
as well, and showed that as perceptions of barriers increased, the likelihood of obtaining followup care decreased. Prior work supports this finding, and has noted various types of barriers to
obtaining Pap care services, ranging from tangible resources (e.g., distance to a provider,
transportation and childcare needs, difficulties in taking time off work; KFF, 2018; Ladoceour,
2010; Nolan, et al., 2014) to emotional barriers (e.g., fear of harmful results, fear of pain,
embarrassment, feeling unable to prevent cervical cancer from continuing to develop; Bellinger
et al., 2015). Present results support more recent initiatives to reduce tangible barriers for those
seeking care, such as the presence of daycare in doctor’s offices (Massachusetts General
Hospital, 2019; Providence Health & Services, 2019) and Medicaid programs providing
transportation to and from doctor’s appointments as a benefit of coverage (Centers for Medicare
& Medicaid Services [CMS], 2016).
Based on review of the items comprising the perceived barriers measure, and the
inclusion of emotion-related barriers, present results may support the need for additional focus
on evaluating emotional barriers and their role in influencing this decision-making process.
Because of this emotional focus, support is also provided by present results for initiatives aimed
at improving patient-provider communication of results and engagement in shared decisionmaking with patients about their care (Ackerson, 2010; Bazargan et al., 2004; Bellinger et al.,
2015). Future work in this area should include the investigation of this relationship more closely
so that education and training of providers can include direction on how best to approach
conversations of abnormal results so that patients’ perceived barriers are addressed.
While the influence of perceived barriers to follow-up was significant for both groups,
this influence was more strongly related to obtaining Pap screening than it was to receiving
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follow-up care after an abnormal Pap, which was counter to hypotheses. This could be due to a
number of factors; however, common threads may be patient-provider communication and
professional connection to resources. The reduced influence of perceived barriers to follow-up
may, in part, be due to the existence of programs intended to cover costs related to diagnostic
and treatment care after receiving abnormal Pap results, such as Every Woman’s Life (EWL).
EWL covers reproductive cancer screenings for women aged 40-64 who meet financial and
residential qualifications, and will additionally cover follow-up care for women who are 18 or
older, have received an abnormal Pap test, and meet qualifications (Every Woman’s Life, 2019).
Unlike experiences with scheduling Pap screening tests, patients are contacted directly by
providers about the need to schedule follow-up care. This contact offers an opportunity to
provide insight that is usually missing when seeking Pap screening, such as financial resources
that may exist, specialist provider options, what to expect from follow-up testing or treatment,
and likely chain of events subsequent to follow-up care. If this information is provided, it may
serve to reduce the influence of barriers in follow-up decision-making.
The final similarity noted across groups was that of increased severity of an abnormal
Pap result as conveyed by a medical provider being related to an increase in perceptions of
susceptibility to cervical cancer. Although not explicitly studied in previous literature, it is
reasonable that a doctor’s statement about the severity of abnormal cells found through one’s Pap
screening would increase their feelings of susceptibility to developing cervical cancer from those
cells in the future. This may be particularly important for providers to be aware of when
communicating results with patients who are Black women, as perceived susceptibility to
cervical cancer was only influential in predicting engagement in follow-up care for this group,
and served as the most influential factor in the model for Black women. Even with a lack of
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research evaluating engagement in cervical cancer follow-up care, these findings bear
resemblance to previous work focused on Pap screening behavior that has noted a relationship
between perceived susceptibilities predicting engagement in Pap screening (Parrish, 2016; Strohl
et al., 2015). Thus, tapping into perceived susceptibility when discussing Pap results may serve
as a unique motivating factor for receiving follow-up care among Black women.
There were a few other paths that differed between racial groups, as well. Severity of
abnormal Pap results as conveyed by a medical provider only predicted perceptions of cervical
cancer severity among Black women. Interestingly, though, perceived severity did not
significantly predict receipt of follow-up care for either racial group. These results indicate that
although emphasizing the severity of one’s abnormal Pap results may increase perceptions of
cervical cancer severity, this may not be beneficial, as perceptions of cervical cancer severity are
not predictive of follow-up service use. Thus, these findings support limiting emphasis on
severity in working toward the goal of improving engagement in follow-up care.
Conversely, perceptions of benefits to follow-up care predicted receipt of follow-up care
only among White women. This may be related to previous literature which has evaluated Black
women’s perceptions of abnormal Pap results, and shown common discussions around fear that
follow-up testing will show unwanted results that may require treatment that could reduce or
eliminate fertility, or the belief that they would know if something were wrong with their bodies
(i.e., they would be experiencing noticeable symptoms; Ackerson, 2010; Bellinger et al., 2015).
The relationship of perceived benefits was also more influential for predicting receipt of followup care for White women than it was in predicting Pap screening behavior. This may make sense
in that Pap smears are commonly regarded as routine care where one expects to receive a null
result confirming that there are no problems, while any follow-up care for an abnormal Pap result
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is used to search for a false positive in the initial Pap result or to determine how severe cervical
dysplasia is and what treatment will be necessary moving forward. Ergo, follow-up care may be
seen as more beneficial in ruling out the presence of abnormal cells or preventing cervical cancer
development.
Although not part of the originally hypothesized model, analyses suggested adding paths
from severity of an abnormal Pap result as conveyed by a medical provider predicting perceived
benefits and barriers to follow-up care. These paths were found only to be significant for White
women, and showed that as the doctor’s communication of Pap results portrayed increased
severity, perceptions of benefits to follow-up care decreased and perceptions of barriers to
follow-up care increased. Taken in sum with the rest of the model results, this may suggest that
medical providers’ communication of the severity of abnormal results may result in substantial
amounts of fear of cervical cancer diagnoses. Fear, related to physical and emotional
experiences, has been discussed in some previous literature as a barrier to continued cervical
cancer testing and care (Ackerson, 2010; Bellinger et al., 2015). It is possible that some patients
interpret their abnormal results as being equivalent to a cervical cancer diagnosis during these
communications, rather than being abnormal growth that is likely able to be controlled and
eliminated with early intervention.
If so, this may provide an explanation for why provider communication of severity of
abnormal Pap results and perceptions of cervical cancer severity do not function as expected
within the model. For instance, the introduction of fear of imminent cervical cancer diagnosis
could explain why perceptions of cervical cancer severity are not predictive of engagement in
follow-up care for either racial group, as well as why provider communication of Pap results is
related to increased perceptions of cervical cancer susceptibility for both groups. Combined with
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racial differences, this may additionally provide rationale as to why provider communication of
Pap results is related to increased perception of cervical cancer severity for Black women, as
well as increased perception of barriers and decreased perception of benefits for White women.
Hypotheses 4a-c.
The goal of the final set of hypotheses was to determine the role, if any, of ethnic
centrality in decisions to obtain follow-up care after receiving an abnormal Pap result. Previous
work evaluating decisions among Black women to obtain Pap screening indicated that the
salience of one’s ethnic identity was influential (Bellinger et al., 2015). However, in their work,
the salience of ethnic identity was found to serve as both a protective and predictive factor of Pap
screening among different women. Some Black women reported apprehension in receiving care
for fear of receiving abnormal results that would require fertility-compromising treatment to
correct, while others evoked the Strong Black Woman schema to explain their felt need to put
the health and needs of others before themselves. Still others related the Strong Black Woman
schema to their feelings that their identity was tied to a need to take care of themselves so that
they may care for others, as well as a responsibility to educate others about testing (Bellinger et
al., 2015).
Present results provided no support for the first parts of hypothesis 4, which evaluated the
role of ethnic centrality as a moderator in the relationships between (a) perceived susceptibility
and (b) severity of cervical cancer and obtaining follow-up care. However, the analyses did
indicate that ethnic centrality was significantly related to both perceived susceptibility and
severity for both racial groups. As a result, ethnic centrality was entered into the overall HBM
model and tested as a predictor of both perceived susceptibility and severity, rather than as a
moderator.
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In the overall model, ethnic centrality did not predict perceptions of susceptibility to
cervical cancer for either group, and predicted perceptions of cervical cancer severity among
Black – but not White – women. This latter relationship showed that as feelings of ethnic
centrality increased, perceptions of the severity of cervical cancer increased. However, as
indicated above, perceived severity of cervical cancer was not significantly related to receipt of
follow-up care for either racial group. Further, although not originally hypothesized,
modification indices suggested that a path be added between ethnic centrality and perceived
benefits of follow-up care. Interestingly, although it was more influential for Black women, this
path was significant for both racial groups, and indicated that higher levels of ethnic centrality
were related to increased perceptions of benefits to obtaining follow-up care.
Taken together, these findings suggest that the salience of Black women’s ethnic identity
plays a role in increasing perceptions of the severity of cervical cancer and the benefits provided
by obtaining follow-up care after an abnormal Pap result; but that, ultimately, because neither
perceived severity nor benefits represent a significant influence in Black women’s decision to
receive follow-up care, a significant influence of ethnic centrality in this decision-making
process was not found. Thus, although ethnic centrality was included in this model in an attempt
to account for a portion of the decision-making process for Black women, it did not provide any
additional insight in its current form. However, reflecting upon the findings of Bellinger and
colleagues (2015), participants’ experiences of their ethnic identity may be interpreted as being
heavily intertwined with their feminine identity, as they frequently discuss fears related to
potential loss of fertility and the importance of being able to one day enter into or maintain their
current role(s) as a mother, caretaker, or otherwise matriarchal presence. Thus, it may be
beneficial for future work to incorporate salience of feminine identity or womanhood and

93
fertility into this decision-making process along with salience of ethnic identity in order to glean
insight into how identification with specific identities may influence the emotional factors at play
in the process of deciding to receive follow-up care.
Additional differences between the final invariant model for H3 and the present model
included relaxing the path from age predicting perceived benefits of follow-up care and
constraining the path from severity of abnormal Pap results as conveyed by a medical provider
predicting perceived barriers to follow-up care. For the first change, model indices suggested that
the model would be stronger if this path were relaxed, and resulted in this path between age
negatively predicting the perception of benefits to follow-up care only being significant among
White women. The latter change resulted from model values indicating similarities between
groups, and showed that increased severity of abnormal Pap results as conveyed by a medical
provider was related to increased perception of barriers to follow-up care across racial groups.
As discussed previously, this finding may indicate that when discussing abnormal Pap results
with patients, a heavy focus on the severity of the abnormal Pap results may result in the
opposite of the intended effect – where patients come to perceive even more barriers to receiving
follow-up care, and may experience an increase in emotional barriers as they feel more fear
around having additional testing done or learning the results of diagnostic testing. Thus, current
results indicate that to improve engagement in follow-up care, it may be beneficial for providers
to reduce the conversational focus on result severity, while placing more focus on assessing
patient perception of barriers to receiving necessary follow-up care and assisting patients in the
removal of these barriers.
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Exploratory Analyses.
Due to previous work indicating that cues to action from medical providers have been
found to increase rates of Pap screening (Bazargan, 2004; Bellinger et al., 2015), an exploratory
chi square was conducted as part of hypothesis 1 to determine whether doctor recommendation
influenced the disparities seen in rate of follow-up care attainment between racial groups.
Because this analysis showed that accounting for doctor recommendation to receive follow-up
care made rates of follow-up care receipt equal across Black and White women, it appeared to be
an important factor to be included in the overall model to aid in the explanation of this decisionmaking process for both racial groups.
The final invariant model for H4c was used to build the baseline model for these
analyses, and was modified to include the factor of doctor recommendation to receive follow-up
care. In the final invariant model for this exploratory analysis, three paths with doctor
recommendation as the predictor were significant. Altogether, the inclusion of doctor
recommendation as a factor in the path model accounted for an additional 30 and 16 percent of
the variance in follow-up care decision-making among Black and White women, respectively.
Doctor recommendation was a significant direct predictor of follow-up care receipt among both
racial groups, and this path served as the most influential path in the model for each group.
The other two paths emanating from doctor recommendation were only significant
among White women, and indicated that receiving a recommendation from a medical provider to
obtain follow-up care was associated with increased perceptions of benefits and decreased
perceptions of barriers to follow-up care. These results are promising, as they suggest that when
doctors make recommendations for White women to obtain follow-up care, they may be
discussing some of the benefits of these services and be addressing barriers that come up for
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patients. When taking the entire model into consideration this becomes even more influential, as
higher perception of benefits and lower perception of barriers to follow-up care are predictive of
engagement in follow-up care among White women. Thus, doctor recommendation to receive
follow-up care seems to be operating effectively through these channels to improve uptake of
follow-up services among White women.
Conversely, doctor recommendation to receive follow-up care did not operate through
any of the HBM facets in Black women’s decision-making processes. One possible explanation
for this could be that doctor recommendations for care are operating through factors not
represented in the HBM. Prior work has discussed the role of health locus of control in screening
behavior among Black women, and has found that those who believe that healthcare
professionals are responsible for their health are more likely to be up-to-date in their Pap
screening (Bazargan et al., 2004). Decisions to obtain follow-up care may operate similarly, with
those having an external locus of control being more likely to follow their doctor’s
recommendations to receive care.
Another possibility is that the types of messaging used by providers is too inconsistent to
form relationships between the HBM variables that are present. While it may be reasonable to
theorize that doctor recommendation could operate through factors such as perceived
susceptibility, severity, benefits, and barriers, some providers may emphasize the benefits of
receiving follow-up care more during conversations with patients, while others focus more on
susceptibility to cervical cancer, and still others focus more on reducing barriers to continued
care. Without consistency across providers in the types and focus(es) of messages used to
recommend follow-up care, it is unreasonable to expect that significant associations between
these factors would form. As previously noted, literature has shown that while White women are
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likely to receive their primary care services from physician’s offices, Black women are more
likely to receive care from clinics, hospital emergency departments, or outpatient facilities
(Waknine, 2005). Because sources of care for Black women are more variable than they are for
White women, it is likely that the types and focuses of messages their providers use when
conveying screening results and recommendations for follow-up care are more varied, as well.
Limitations and Future Directions
Despite overall support for some hypotheses, several limitations must be considered. One
limitation was the use of a cross-sectional correlational design, which prevents drawing any
causal inferences. This study also utilized a relatively small sample size of those who did not
receive follow-up care (i.e., 106 out of 660 who had abnormal results), thus only a very small
subset of Black and White women included in these analyses reported not receiving follow-up
care (60 and 46, respectively).
Relying on self-reports of health behaviors and service receipt, which are likely to
contain some measurement error, is also a limitation of the present study. Participants may not be
able to accurately recall the frequency or timing of participation in health services, may not be
able to recall titles of diagnoses and treatments accurately, and/ or may feel pressure to report
receiving recommended preventive cervical health services (Bhandari & Wagner, 2006).
This sample was also more highly educated, with 68.95% having received education
beyond high school. However, this sample also had insured rates of 89.49%, which mirrored
current U.S. health insurance coverage rates (91.5% of citizens covered in 2018; U.S. Census
Bureau, 2019a), and the $50,000 median income of the sample is lower than that reported by the
census ($61,937; U.S. Census Bureau, 2019b). Still, generalizability of the sample may
somewhat be limited. This demographic distribution is likely a byproduct of internet sampling,
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another limitation of this study. Samples collected through online platforms are characterized by
possessing more privilege in terms of access to the internet and other types of resources. Thus,
the results of the present study likely represent the upper bounds of negative outcomes that may
have much lower bounds for those with less privilege.
Although Amazon Mechanical Turk has the ability to recruit a nationally representative
sample, individuals are still in control of which studies they self-select into. Therefore, it is
possible that those who decided to self-select into a study about women’s health services differ
from the general population.
This study also did not assess sources of care, continuity of care, effectiveness of
provider communication, the role of feminine identity/ womanhood and fertility, or health locus
of control. Previous research has indicated that these factors may play an important role in
decisions to engage in certain health services (Bazargan et al., 2004; Bellinger et al., 2015).
Future studies should incorporate these variables alongside the others present in this study, as
understanding the potential influence of each of these can serve to further inform beneficial
focuses and methods for community and provider interventions.
Of particular importance moving forward is understanding the influence of emotional
barriers to follow-up care (e.g., fear of what follow-up results may show). Additional
investigation should focus on the weight of emotional barriers to follow-up compared to more
traditionally discussed barriers related to tangible resources (e.g., lack of access to providers,
cost, lack of time). Understanding which aspects of perceived barriers are more influential is
likely to offer further insight into how providers can tailor their messages to more effectively
target specific concerns that function as barriers to continued care.
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General Implications
While using self-report data is a limitation of this study, online surveying resulted in a
geographically representative national sample of cisgender women, allowed for the recruitment
of a large number of Black women, and provided insight into some of the factors that predict
engagement in Pap screening and follow-up care for Black and White women after receiving an
abnormal Pap result. A particularly important implication of the present study is that expanding
knowledge and training among medical providers would likely be beneficial in increasing the
rates at which providers recommend appropriate follow-up care for their Black patients, thereby
increasing the utilization of follow-up care among Black women, generally.
Although the indicator of doctor recommendation to seek follow-up care is based on
participants’ perceptions and understanding, Black women as a group were still less likely to
report having received a recommendation to get follow-up care. This finding may reflect that
providers are less likely to recommend follow-up care to Black women. Alternatively, findings
may the result of failed communication between providers and their patients, where the provider
did recommend follow-up care but the message was not received by the patient. Previous
qualitative literature evaluating follow-up service use among Black women has noted the
presence of miscommunication between providers and patients, and the resulting delay or
discounting of follow-up service use (Bellinger et al., 2015). Taken together with previous work,
current findings provide support for an increase in funding and resources to educate providers
about current relevant medical standards and guidelines for cervical care, as well as the
disparities existing in provider recommendations for follow-up between racial groups.
However, the present research also suggests that one standardized method of
communicating abnormal Pap results and the need for follow-up diagnostic tests or treatment
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may not be equally effective for Black and White women. Instead, the focus of patient-provider
communications about abnormal Pap results and recommended follow-up care should be tailored
to include information indicated to be more influential for Black or White women, as
appropriate. Present results support limiting discussion of points that serve to increase
perceptions of cervical cancer severity, and to include a larger focus on reducing perceptions of
barriers, for both racial groups. For patients who are White women, it may be more beneficial for
providers to also focus the conversation around the benefits of receiving follow-up testing, while
for Black women it may be more beneficial to focus a larger portion of the conversation around
points that increase understanding of their personal susceptibility to cervical cancer. Thus, these
findings support the provision of additional provider training related to effective communication
with patients and the need for diverse messaging that speaks to different patients’ values and
concerns.
Results from the present study additionally indicate that messaging techniques that
incorporate ethnic identity may serve to increase perceptions of the severity of cervical cancer,
but may not be particularly beneficial in persuading Black women to engage in follow-up care.
Conversely, specific doctor recommendation to obtain follow-up care is likely to be the most
beneficial factor influencing engagement in continued care. Therefore, present findings support
direct, specific communication from medical providers about which follow-up services should be
obtained, what each test or treatment is designed to do, and a clear rationale for why this care is
important.
Finally, current results show that access to health insurance remains a significant
predictor of engagement in Pap screening and follow-up care. Thus, this study provides support
for continued policy efforts aimed at increasing access to high quality health coverage, as well as
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efforts to improve coverage for follow-up diagnostic testing and treatment of cervical cell
abnormalities. These results also lend support for continued development and funding of
programs that improve access to care, such as those that provide financial resources outside of
health insurance coverage for those in need of follow-up care. Such efforts have the potential to
improve access follow-up diagnostic tests and treatments for those in need through the reduction
of systemic barriers.
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APPENDIX A:
RESEARCH SUBJECT INFORMATION AND CONSENT FORM
TITLE: Experiences with Women’s Health Services
VCU IRB NO.: HM20014743
PURPOSE OF THE STUDY
The purpose of this research study is to examine the relationships between women’s perceptions,
experiences, and the use of preventive reproductive health services.
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT
If you decide to be in this research study, you will first be asked to respond to brief demographic
items to ensure that you are eligible to participate. If you do not qualify for this study, you will
be informed at this time.
If you do qualify for this study, you will then be asked to complete several online survey
measures asking you about your knowledge and beliefs pertaining to reproductive health care,
your reproductive medical history, and health service use during the previous year.
This study should take no longer than 30 minutes. All of your responses will remain confidential,
so the answers that you provide will not be released to anyone.
RISKS AND DISCOMFORTS
Sometimes discussing personal health issues and behaviors can cause people to become
embarrassed or upset. These questions should not elicit more discomfort than what you might
experience in normal daily interactions. You may stop participating in the research at any time.
If you become upset, you may contact the research team using the information at the end of this
form.
There is also a risk of a loss of confidentiality. However, to minimize this risk, we do not ask for
any identifying information, nor will your user ID be linked to your data.
BENEFITS TO YOU AND OTHERS
You may not get any direct benefit from this study, but the information we learn from people in
this study may help us better understand how people understand and utilize health services in the
United States.
COSTS
There are no costs for participating in this study other than the time you will spend filling out the
questionnaires.
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COMPENSATION
You will be compensated $0.75 for your participation in this research study. In order to receive
compensation, you must correctly answer 5 out of 7 quality assurance questions that are
randomly placed throughout the questionnaire.
CONFIDENTIALITY
Data are being collected only for research purposes. MTurk automatically collects participants’
IP addresses; however, we will not retain your IP address in our saved records or link your
survey responses to your IP addresses in any saved databases, publications, presentations, or any
other format.
Information from the study and your consent to participate may be looked at or copied for
research or legal purposes by Virginia Commonwealth University. What we find from this study
may be presented at conferences or published in scholarly papers, but your name will not ever be
used in these presentations or papers. Your answers will remain confidential, as we will discard
your IP addresses before data is stored and we are not collecting your name or other identifiable
information.
COMPUTER USE
If possible, please take this survey on your personal computer.
VOLUNTARY PARTICIPATION AND WITHDRAWAL
Your participation in this study is voluntary. You may decide to not participate in this study.
Choosing not to participate will result in no penalty or loss of benefit to which you are otherwise
entitled. If you do participate, you may withdraw from the study at any time without penalty.
QUESTIONS
In the future, you may have questions about your participation in this study. If you have any
questions, complaints, or concerns about the research, contact:
Dr. Eric Benotsch
808 W. Franklin St., #208
Richmond, VA 23284
E-mail: ebenotsch@vcu.edu
Phone: 804-828-0133
The researcher/study staff named above is the best person(s) to call for questions about your
participation in this study.
If you have any general questions about your rights as a participant in this study, you may
contact:
Office for Research
Virginia Commonwealth University
800 East Leigh Street, Suite 3000
P.O. Box 980568
Richmond, VA 23298
Telephone: 804-827-2157
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Contact this number to ask general questions, to obtain information or offer input, and to express
concerns or complaints about research. You may also call this number if you cannot reach the
research team or if you wish to talk with someone else. General information about participation
in research studies can also be found at
http://www.research.vcu.edu/human_research/volunteers.htm.
CONSENT
I have been given the chance to read this consent form. I understand the information about this
study. Questions that I wanted to ask about the study have been answered. By clicking “I agree”
below, I am indicating that I understand this consent form and agree to participate. I also verify
that I am 21 years of age or older and live in the United States.



I choose to participate in this study.
I choose to not participate in this study.
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APPENDIX B:
STUDY QUESTIONNAIRE
Instructions: Please answer the following questions to the best of your ability:
[Demographic questions that will be used to determine eligibility for participation in the study]
[Page 1]
1. What state do you currently live in? _____
2. What is your age? ___
[If under the age of 18 or over the age of 65, the respondent will be filtered out of the survey]
[Page 2]
3. Are you of Hispanic, Latino/a, or Spanish origin? (select all that apply):
a. Mexican, Mexican American, Chicano/a
b. Puerto Rican
c. Cuban
d. Another Hispanic, Latino/a, or Spanish origin
e. None
4. Which race best describes you:
• White American
• Black American
• Asian
• American Indian or Alaskan Native
• Native Hawaiian or Other Pacific Islander
• Other________________
[If response is not ‘Black American’, the respondent will be filtered out of the survey]
[Page 3]
5. Which of the following best describes your sexual orientation?
• Heterosexual/ Straight
• Homosexual/ Gay/ Lesbian
• Down-low
• Same gender loving
• Bisexual/ Bi
• Omnisexual/ Pansexual
• Demisexual
• Asexual
• Queer/ Questioning
• Other _______________
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6. Which of the following best describes your gender? [Note: cisgender means identifying with
the sex assigned to you at birth, while transgender means not identifying with the sex
assigned to you at birth]:
• Cisgender Male
• Cisgender Female
• Transgender Male
• Transgender Female
• Non-Binary/ Gender Non-Conforming
• Agender
• Other ____________
[If response is not ‘Cisgender Female’, the respondent will be filtered out of the survey]

7. Thinking about the past year, which option best describes the amount of time that you had
health insurance coverage?
• I was not insured at all in the past year
• I was insured for 1-6 months out of the last year
• I was insured for 7-11 months out of the last year
• I was insured for all 12 months of the last year
IF ANY INSURANCE IN PAST YEAR, BRANCH TO:
8. What type(s) of health insurance plan(s) have you had in the past year?
• Private Insurance
o (Includes: Plans through employers, federal employee plans, plans from the
Marketplace, plans through parents, plans through universities)
• Public Insurance
o (Includes: Military insurance (Tricare), Medicaid, Medicare, veterans
benefits)
Cervical Cancer Screening History
9. Have you ever had a Pap test/ Pap smear done? No
Yes I don’t know
IF YES OR I DON’T KNOW, BRANCH TO:
a. When was the last time that you received a Pap test?
[Even if you are unsure of the exact date, please provide your best estimate.] ___
IF NO, BRANCH TO:
b. Why haven’t you ever had a Pap smear done?
10. Have you had a Pap test in the last 3 years?
No
Yes I don’t know
IF YES, BRANCH TO:
a. How many times have you had a Pap test in the last 3 years?
[Even if you don’t know the exact number, please provide your best estimate] ___
IF NO OR I DON’T KNOW, BRANCH TO:
a. Have you had a Pap test in the last 5 years? No
Yes I don’t know
IF YES, BRANCH TO:
a. How many times have you had a Pap test in the last 5 years?
[Even if you don’t know the exact number, please provide your best estimate] ___
IF NO, BRANCH TO THE END OF THE BLOCK
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HPV Screening History
11. Have you ever had an HPV test?
No
Yes I don’t know
IF YES OR I DON’T KNOW, BRANCH TO:
c. When was the last time that you received an HPV test?
[Even if you are unsure of the exact date, please provide your best estimate.] ___
IF NO, BRANCH TO THE END OF THE BLOCK
12. Have you had an HPV test in the last 3 years? No
Yes I don’t know
IF YES, BRANCH TO:
a. How many times have you had an HPV test in the last 3 years?
[Even if you don’t know the exact number, please provide your best estimate]___
IF NO OR I DON’T KNOW, BRANCH TO:
13. Have you had an HPV test in the last 5 years? No
Yes I don’t know
IF YES, BRANCH TO:
a. How many times have you had an HPV test in the last 5 years?
[Even if you don’t know the exact number, please provide your best estimate]___
IF NO, BRANCH TO THE END OF THE BLOCK
HPV Vaccination History
14. Have you received at least one dose of the HPV vaccine?
___No ___Yes ___I don’t know
IF YES, BRANCH TO →
a. How many doses have you received? Please enter a number. ______
b. How old were you when you received the HPV vaccine? Even if you are unsure,
please enter a numerical age that is your best guess. _____
c. When was your last dose? Even if you are unsure, please enter a numerical date that is
your best guess. __
d. Was the decision to receive the HPV vaccine yours or did a parent decide to have you
vaccinated when you were an adolescent?
___I decided ___A parent decided ___I decided with my parent(s) ___I don’t know
15. Has a doctor ever offered the HPV vaccine to you?

___No ___Yes ___I don’t know

16. Has a doctor ever suggested that you receive the HPV vaccine? ___No ___Yes ___I don’t know
IF YES, BRANCH TO →
1. How old were you when a doctor suggested that you receive the HPV vaccine?
HBM Dimensions for Pap Screening
Subscales from The Health Belief Model Scale for Cervical Cancer and the Pap Smear Test.
Guvenc, G., Akyuz, A., Han Acikel, C. (2011). Health belief model scale for cervical cancer and
Pap smear test: psychometric testing. Journal of Advanced Nursing, 67(2), 428-437. doi:
10.1111/j.1365-2648.2010.05450.x.
Perceived Susceptibility
Strongly Disagree Slightly Slightly Agree Strongly
Disagree
Disagree Agree
Agree
17. It is likely that I will get cervical cancer
in the future
18. My chances of getting cervical cancer in
the next few years are high
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19. I feel I will get cervical cancer sometime
during my life
Perceived Seriousness/ Severity
Strongly Disagree Slightly Slightly Agree Strongly
Disagree
Disagree Agree
Agree
20. The thought of cervical cancer scares me
21. When I think about cervical cancer, my
heart beats faster
22. I am afraid to think about cervical cancer
23. Please select ‘Agree’ for this item (QA)
24. Problems I would experience with
cervical cancer would last a long time
25. Cervical cancer would threaten a
relationship with my partner or spouse
26. If I had cervical cancer my whole life
would change
27. If I developed cervical cancer, I would
not live longer than 5 years
Perceived Barriers
Strongly Disagree Slightly Slightly Agree Strongly
Disagree
Disagree Agree
Agree
28. I am afraid to have a Pap smear test for
fear of a bad result
29. I am afraid to have a Pap spear test
because I don’t know what will happen
30. I don’t know where to go for a Pap
smear test
31. I would be ashamed to lie on a
gynecologic examination table and show
my private parts to have a Pap smear test
32. Having a Pap smear test takes too much
time
33. Having a Pap smear test is too painful
34. Health professionals doing Pap smear
tests are rude to women
35. I neglect or cannot remember to have a
Pap smear test regularly
36. I have other problems more important
than having a Pap smear test in my life
37. I am too old to have a Pap smear test
regularly
38. There is no health center close to my
house to have a Pap smear test
39. If there is cervical cancer in my destiny,
having a Pap smear test cannot prevent it
40. I prefer a female doctor to conduct a Pap
smear test
41. I will never have a Pap smear test if I
have to pay for it
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Perceived Benefits
Strongly Disagree Slightly Slightly Agree Strongly
Disagree
Disagree Agree
Agree
42. If I have a Pap smear test regularly and
the result is good, I don’t need to worry
too much about cervical cancer
43. Having regular Pap smear tests will help
to find changes to the cervix before they
turn into cancer
44. If cervical cancer was found at a regular
Pap smear test, its treatment would not be
so bad
45. I think that having a regular Pap smear
test is the best way for cervical cancer to
be diagnosed early
46. Having regular Pap smear tests will
decrease my chances of dying from
cervical cancer
HBM Dimensions Modified for Follow-Up Care
Modified subscales from the Health Belief Model Scale for Cervical Cancer & the Pap Smear Test.
Perceived Barriers
Strongly Disagree Slightly Slightly Agree Strongly
Disagree
Disagree Agree
Agree
47. I am afraid to have follow-up diagnostic
tests done for fear of a bad result
48. I am afraid to have follow-up diagnostic
tests done because I don’t know what
will happen
49. I don’t know where to go for follow-up
diagnostic tests
50. Please select strongly disagree for this
item. (QA)
51. I would be ashamed to lie on a
gynecologic examination table and show
my private parts to have follow-up
diagnostic tests
52. Having follow-up diagnostic tests takes
too much time
53. Having follow-up diagnostic tests is too
painful
54. Health professionals doing follow-up
diagnostic tests are rude to women
55. I neglected or could not remember to
have follow-up diagnostic tests done
56. I have other problems in my life that are
more important than having follow-up
diagnostic tests
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57. There is no health center close to my
house to have a Pap smear test
58. If there is cervical cancer in my destiny,
having follow-up diagnostic tests cannot
prevent it
59. I prefer a female doctor to conduct
follow-up diagnostic tests
60. I will never have follow-up diagnostic
tests if I have to pay for it
Perceived Benefits
Strongly Disagree Slightly Slightly Agree Strongly
Disagree
Disagree Agree
Agree
61. Having treatment done after getting
abnormal Pap results will help eliminate
dangerous cells in the cervix before they
turn into cancer
62. If cervical cancer was found during
follow-up tests after a Pap smear, its
treatment would not be so bad
63. I think that having diagnostic tests done
after abnormal Pap results is a good way
for cervical cancer to be diagnosed early
64. Having treatment done after getting
abnormal Pap results will decrease my
chances of dying from cervical cancer
Ethnic Centrality
Fuligni, A. J., Witkow, M., & Garcia, C. (2005). Ethnic identity and the academic adjustment of
adolescents from Mexican, Chinese, and European backgrounds. Developmental Psychology, 41,
799–811. http://dx.doi.org/10.1037/0012-1649.41.5.799
65. Please fill in:
In terms of ethnic group, I consider myself to be: ____________________
Instructions: The next set of questions asks you about your ethnicity. Looking at the items
below, please tell me how much you agree or disagree with each statement, thinking about how
you felt during the past year
Strongly Disagree Neither Agree Strongly
Disagree
Agree or
Agree
How well do these statements describe you?
Disagree
66. Overall, being a member of my ethnic group has
very little to do with how I feel about myself.
67. In general, being a member of my ethnic group is
an important part of my self-image.
68. Being a part of my ethnic group is an important
reflection of who I am.
69. Being a part of my ethnic group is important for
my social relationships.
70. All of my friends say that I would make an
excellent rhinoceros.
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71. Being a part of my ethnic group is important to my
sense of what kind of person I am.
72. My ethnicity is
(1) Asian or Asian American, including Chinese, Japanese, and others
(2) Black or African American
(3) Hispanic or Latino, including Mexican American, Central American, and others
(4) White, Caucasian, Anglo, European American; not Hispanic
(5) American Indian/Native American
(6) Mixed; Parents are from two different groups
(7) Other (write in): _____________________________________
73. My father's ethnicity is:
(1) Asian or Asian American, including Chinese, Japanese, and others
(2) Black or African American
(3) Hispanic or Latino, including Mexican American, Central American, and others
(4) White, Caucasian, Anglo, European American; not Hispanic
(5) American Indian/Native American
(6) Mixed; Parents are from two different groups
(7) Other (write in): _____________________________________
74. My mother's ethnicity is:
(1) Asian or Asian American, including Chinese, Japanese, and others
(2) Black or African American
(3) Hispanic or Latino, including Mexican American, Central American, and others
(4) White, Caucasian, Anglo, European American; not Hispanic
(5) American Indian/Native American
(6) Mixed; Parents are from two different groups
(7) Other (write in): _____________________________________
Personal Health History - Abnormal Pap Test Results – Last Pap
Instructions: Consider the last Pap test you had:
75. Were the results of the Pap smear normal or abnormal?
Normal
Abnormal
I don’t know
76. More specifically, were your results:
Result
Result Full Name
1. Normal
2. ASC-US Atypical Squamous Cells of
Undetermined Significance
3. LSIL
Low-Grade Squamous
Intraepithelial Lesion
4. ASC-H Atypical Squamous Cells,
cannot exclude HSIL
5. HSIL
High-Grade Squamous
Intraepithelial Lesion
6. AGC
Atypical Glandular Cells

Result Description
No abnormal cells present
Abnormal cells have been found, but they may or
may not be dangerous
Mildly abnormal cells
Changes have been found that raise concern for
the presence of HSIL
Abnormal cells that are more serious

Changes have been found in glandular cells raise
concern for the presence of precancer or cancer
7. My Pap smear test was abnormal, but I don’t know what the result was
8. I never got my Pap smear test results
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IF NO ABNORMAL RESULT OR NEVER GOT PAP RESULTS, BRANCH TO ALL PAP TEST
HISTORY (Personal Health History - Abnormal Pap Test Results – All Pap History):
IF ABNORMAL PAP RESULT RECEIVED (B-G), BRANCH TO:
77. When your doctor told you about your abnormal Pap results:
Did the doctor state:
a.
b.
c.
d.
e.

Yes I don’t
know

No

Yes I don’t
know

That the results were potentially harmful to your health?
That you should receive follow-up care?
That you needed to receive follow- up care?
That they wanted you to have another Pap test done?
That they wanted you to have tests other than another Pap test done?

Did you feel:
a.
b.
c.
d.
e.

No

That the results were potentially harmful to your health?
That you should receive follow-up care?
That you needed to receive follow- up care?
That you should have another Pap test done?
That you should have tests other than another Pap test done?

78. What care did your doctor recommend after your abnormal Pap result? Please select all that apply.
[checkbox options]
a. None
b. Receive Pap AND HPV testing in 5 years
c. Receive a Pap test again in 3 years
d. Receive a Pap test again in 12 months
e. Colposcopy (uses microscope to look for abnormal cells)
f. Biopsy (removing tissue/ cells to rest for abnormalities)
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells)
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells)
i. Cryotherapy (uses liquid gas to freeze abnormal cells)
j. Laser therapy (uses laser to remove abnormal cells)
k. I don’t know
79. What care did you receive after your abnormal Pap result? Please select all that apply.
[checkbox options]
a. None
b. Receive Pap AND HPV testing in 5 years
c. Receive a Pap test again in 3 years
d. Receive a Pap test again in 12 months
e. Colposcopy (uses microscope to look for abnormal cells)
f. Biopsy (removing tissue/ cells to rest for abnormalities)
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells)
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells)
i. Cryotherapy (uses liquid gas to freeze abnormal cells)
j. Laser therapy (uses laser to remove abnormal cells)
k. I don’t know
IF ‘NONE’ SELECTED (OPTION A), BRANCH TO:
80. Why did/ didn’t you decide to receive follow-up care?_______________
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IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (B-K), BRANCH TO:
81. Later the doctor told you about your abnormal Pap results, about how long did it take for you
to schedule an appointment to get follow-up care?
a. I scheduled an appointment that same day
b. A few days
c. A few weeks
d. A few months
e. More than a few months
82. After the doctor told you about your abnormal Pap results, about how long did it take for you
to receive follow-up care?
a. I received follow-up care that same day
b. A few days
c. A few weeks
d. A few months
e. More than a few months
f. I did not receive follow-up care
IF ‘I DID NOT RECEIVE FOLLOW-UP CARE’ IS SELECTED (F), BRANCH TO:
83. Why did/ didn’t you decide to receive follow-up care?_______________
IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (A-E), BRANCH TO:
84. What results did you receive from this care?
Result
Result Full Name
Result Description
a. Normal
No abnormal cells present
b. ASC-US Atypical Squamous Cells of Abnormal cells have been found, but they may or
Undetermined Significance may not be dangerous
c. LSIL/
Low-Grade Squamous
Mildly abnormal cells
CIN I
Intraepithelial Lesion
d. ASC-H Atypical Squamous Cells,
Changes have been found that raise concern for
cannot exclude HSIL
the presence of HSIL
e. HSIL
High-Grade Squamous
Abnormal cells that are more serious
Intraepithelial Lesion
f. CIN II
Moderately abnormal cells
g. CIN III
Severely abnormal cells or carcinoma in situ
h. AGC
Atypical Glandular Cells
Changes have been found in glandular cells raise
concern for the presence of precancer or cancer
i. AIS
Adenocarcinmoa in Situ
Cancer cells found in glandular tissue of the
endocervix
j. My follow-up test was abnormal, but I don’t know what the result was
k. I never got my follow-up test results
85. What care did your doctor recommend to you after you received this result? Please select all
that apply. [checkbox options]
a. None
b. Receive Pap AND HPV testing in 5 years
c. Receive a Pap test again in 3 years
d. Receive a Pap test again in 12 months
e. Colposcopy (uses microscope to look for abnormal cells)
f. Biopsy (removing tissue/ cells to rest for abnormalities)
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells)
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h.
i.
j.
k.
l.

Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells)
Cryotherapy (uses liquid gas to freeze abnormal cells)
Laser therapy (uses laser to remove abnormal cells)
Follow up with a specialist
I don’t know

86. Why did/ didn’t you decide to receive follow-up care?_______________
IF NO ABNORMAL PAP RESULT RECEIVED ON LAST PAP, BRANCH TO:
Personal Health History - Abnormal Pap Test Results – All Pap History
Instructions: Consider all of the Pap tests you have ever had:
87. Have you ever had abnormal results?
No
Yes

I don’t know

88. Please indicate all of the following results you have ever received:
Result
Result Full Name
Result Description
1. Normal
No abnormal cells present
2. ASC-US Atypical Squamous Cells of Abnormal cells have been found, but they may or
Undetermined Significance may not be dangerous
3. LSIL
Low-Grade Squamous
Mildly abnormal cells
Intraepithelial Lesion
4. ASC-H Atypical Squamous Cells,
Changes have been found that raise concern for
cannot exclude HSIL
the presence of HSIL
5. HSIL
High-Grade Squamous
Abnormal cells that are more serious
Intraepithelial Lesion
6. AGC
Atypical Glandular Cells
Changes have been found in glandular cells raise
concern for the presence of precancer or cancer
7. My Pap smear test was abnormal, but I don’t know what the result was
8. I never got my Pap smear test results
IF NORMAL, BRANCH TO END OF BLOCK
IF ‘I NEVER GOT MY PAP SMEAR TEST RESULTS,’ BRANCH TO END OF BLOCK
IF ABNORMAL PAP RESULT RECEIVED (B-G), BRANCH TO:
89. When your doctor told you about your abnormal Pap results:
Did the doctor state:
a.
b.
c.
d.
e.

Yes I don’t
know

No

Yes I don’t
know

That the results were potentially harmful to your health?
That you should receive follow-up care?
That you needed to receive follow- up care?
That they wanted you to have another Pap test done?
That they wanted you to have tests other than another Pap test done?

Did you feel:
f.
g.
h.
i.
j.

No

That the results were potentially harmful to your health?
That you should receive follow-up care?
That you needed to receive follow- up care?
That you should have another Pap test done?
That you should have tests other than another Pap test done?
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90. What care did your doctor recommend after your abnormal Pap result? Please select all that apply.
[checkbox options]
a. None
b. Receive Pap AND HPV testing in 5 years
c. Receive a Pap test again in 3 years
d. Receive a Pap test again in 12 months
e. Colposcopy (uses microscope to look for abnormal cells)
f. Biopsy (removing tissue/ cells to rest for abnormalities)
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells)
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells)
i. Cryotherapy (uses liquid gas to freeze abnormal cells)
j. Laser therapy (uses laser to remove abnormal cells)
k. I don’t know
91. What care did you receive after your abnormal Pap result? Please select all that apply.
[checkbox options]
a. None
b. Receive Pap AND HPV testing in 5 years
c. Receive a Pap test again in 3 years
d. Receive a Pap test again in 12 months
e. Colposcopy (uses microscope to look for abnormal cells)
f. Biopsy (removing tissue/ cells to rest for abnormalities)
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells)
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells)
i. Cryotherapy (uses liquid gas to freeze abnormal cells)
j. Laser therapy (uses laser to remove abnormal cells)
k. I don’t know
IF ‘NONE’ SELECTED (OPTION A), BRANCH TO:
92. Why did/ didn’t you decide to receive follow-up care?_______________
IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (B-K), BRANCH TO:
93. After the doctor told you about your abnormal Pap results, about how long did it take for you
to schedule an appointment to get follow-up care?
a. I scheduled an appointment that same day
b. A few days
c. A few weeks
d. A few months
e. More than a few months
94. After the doctor told you about your abnormal Pap results, about how long did it take for you
to receive follow-up care?
a. I received follow-up care that same day
b. A few days
c. A few weeks
d. A few months
e. More than a few months
f. I did not receive follow-up care
IF ‘I DID NOT RECEIVE FOLLOW-UP CARE’ IS SELECTED (F), BRANCH TO:
95. Why did/ didn’t you decide to receive follow-up care?_______________
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IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (A-E), BRANCH TO:
96. What results did you receive from this follow-up care?
Result
Result Full Name
Result Description
a. Normal
No abnormal cells present
b. ASC-US Atypical Squamous Cells of Abnormal cells have been found, but they may or
Undetermined Significance may not be dangerous
c. LSIL/
Low-Grade Squamous
Mildly abnormal cells
CIN I
Intraepithelial Lesion
d. ASC-H Atypical Squamous Cells,
Changes have been found that raise concern for
cannot exclude HSIL
the presence of HSIL
e. HSIL
High-Grade Squamous
Abnormal cells that are more serious
Intraepithelial Lesion
f. CIN II
Moderately abnormal cells
g. CIN III
Severely abnormal cells or carcinoma in situ
h. AGC
Atypical Glandular Cells
Changes have been found in glandular cells raise
concern for the presence of precancer or cancer
i. AIS
Adenocarcinmoa in Situ
Cancer cells found in glandular tissue of the
endocervix
j. My follow-up test was abnormal, but I don’t know what the result was
k. I never got my follow-up test results
97. What care did your doctor recommend to you after you received this result? Please select all
that apply. [checkbox options]
a. Receive Pap AND HPV testing in 5 years
b. Receive a Pap test again in 3 years
c. Receive a Pap test again in 12 months
d. Colposcopy (uses microscope to look for abnormal cells)
e. Biopsy (removing tissue/ cells to rest for abnormalities)
f. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells)
g. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells)
h. Cryotherapy (uses liquid gas to freeze abnormal cells)
i. Laser therapy (uses laser to remove abnormal cells)
j. Follow up with a specialist
k. None
l. I don’t know
98. Why did/ didn’t you decide to receive follow-up care?_______________
Personal Medical History
No
99.
100.
101.
102.
103.
104.
105.

Yes

Do you have a chronic health condition?
Do you have an auto-immune disorder?
Do you have a reproductive health issue?
Have you ever been diagnosed with cervical cancer?
Have you ever been diagnosed with breast cancer?
Have you ever been diagnosed with ovarian cancer?
Have you ever been diagnosed with any other form of cancer?
106.

Have you ever been treated for cervical cancer?

No

Yes
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IF YES, BRANCH TO:
a. What type of treatment(s) did you receive for cervical cancer? [checkbox options]
a. Surgery
b. Radiation
c. Chemotherapy
d. Targeted therapy
e. Immunotherapy
f. I don’t know
107. Have you had a hysterectomy?
___No __Yes ___I don’t know
IF YES, BRANCH TO:
a. Did you have your cervix removed during your hysterectomy?
___No __Yes ___I don’t know
108. Were you exposed to DES while your mother was pregnant? No __Yes ___I don’t know
109. Have you been diagnosed with HIV?
Family Medical History
Have any of your immediate family members (i.e., siblings,
parents, aunts, grandparents) been diagnosed with:
110. Cervical cancer?
111. Breast cancer?
112. Ovarian cancer?
113. Any other form of cancer?

___No __Yes
No

Yes

I don’t
know

[Other demographic questions]
114. How many people live in your household? ______
115. How many of the people living in your household are dependent children? ______
116. Please report the amount that best describes your household yearly income BEFORE taxes
(Note: this amount should include all income, including veterans’ payments, child support,
alimony, and assistance from outside of the household; however, it should exclude food
stamps and housing subsidies): ______
117. Highest level of education completed:
• Middle school
• High school
• GED
• Vocational school
• Associates Degree
• Bachelor Degree
• Graduate Degree (Masters, Doctorate, etc.)
118. Of the following, please choose the option that best describes your highest level of
employment (e.g., if you have both a part-time and a full-time job, choose "full time"):
• Not employed
• Student
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•
•
•

Employed part-time
Employed full-time
Retired

119. Relationship Status:
• Not currently dating or in a relationship
• In a newer relationship with 1 person (less than 12 months)
• In a long-term relationship with 1 person (12 months or longer)
• Married
• Dating/ in a relationship with more than 1 person
120. Which of the following best describes your gender? [Note: cisgender means identifying
with the sex assigned to you at birth, while transgender means not identifying with the sex
assigned to you at birth]:
• Cisgender Male
• Cisgender Female
• Transgender Male
• Transgender Female
• Non-Binary/ Gender Non-Conforming
• Agender
• Other ____________
121. Which race best describes you:
• White American
• Black American
• Asian
• American Indian or Alaskan Native
• Native Hawaiian or Other Pacific Islander
• Biracial or Multiracial
• Other________________
122. What do you think this survey is about? (QA) _____________________
123. Random code assignment. “Please type the code you see displayed here.” __________
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Appx C:
U.S. Census Bureau State Region Designations
REGION 1: NORTHEAST
Division 1: New England
Connecticut
(07)
Maine
(20)
Massachusetts
(22)
New Hampshire
(30)
Rhode Island
(40)
Vermont
(46)
REGION 2: MIDWEST
Division 3: East North Central
Illinois
(14)
Indiana
(15)
Michigan
(23)
Ohio
(36)
Wisconsin
(50)

REGION 3: SOUTH
Division 5: South Atlantic
Delaware
(08)
District of Columbia
(09)
Florida
(10)
Georgia
(11)
Maryland
(21)
North Carolina
(34)
South Carolina
(41)
Virginia
(47)
West Virginia
(49)
Division 7: West South Central
Arkansas
(04)
Louisiana
(19)
Oklahoma
(37)
Texas
(44)

Division 2: Middle Atlantic
New Jersey
(31)
New York
(33)
Pennsylvania
(39)

Division 4: West North Central
Iowa
(16)
Kansas
(17)
Minnesota
(24)
Missouri
(26)
Nebraska
(28)
North Dakota
(35)
South Dakota
(42)

Division 6: East South Central
Alabama
(01)
Kentucky
(18)
Mississippi
(25)
Tennessee
(43)
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REGION 4: WEST
Division 8: Mountain
Arizona
Colorado
Idaho
Montana
Nevada
New Mexico
Utah
Wyoming

(03)
(06)
(13)
(27)
(29)
(32)
(45)
(51)

Division 9: Pacific
Alaska
(02)
California
(05)
Hawaii
(12)
Oregon
(38)
Washington
(48)

U.S. Census Bureau, Population Division. (2017). Census Bureau Region and Division Codes
and Federal Information Processing System (FIPS) Codes for States, 2016. Available from:
https://www2.census.gov/programs-surveys/popest/geographies/2016/state-geocodes-v2016.xls

